5/3,AB/61 (Item 2 from file: 764)
IALOG(R)File 764:BCC Market Research
:) 2003 Business Communication Co. All rts. reserv.

:157778

MMERCIAL BIOTECHNOLOGY INDUSTRY REVIEW: %ANTIBODIES%: PREVENTING %PSEUDOMONAS%-INDUCED PNEUMONIA

in Title: COMMERCIAL BIOTECHNOLOGY INDUSTRY REVIEW
ub. Date: APRIL 2001
Source: BUSINESS COMMUNICATIONS COMPANY, INCORPORATED
elephone: (203) 853-4266
rd Count: 287 (1 pp.)
Language: English

Country: UNITED STATES
Industry: BIOTECHNOLOGY, HEALTH CARE
mpany Names (DIALOG Generated): Conference on Antimicrobial Agents and Chemotherapy ; InterMune Pharmaceuticals Inc ; Medical College of Wisconsin ; University of California San

r SELECT statement is:
s pcrV

Items	File
88	2: INSPEC_1969-2003/Jun W2
20	5: Biosis Previews(R)_1969-2003/Jun W2
174	6: NTIS_1964-2003/Jun W3
105	8: Ei Compendex(R)_1970-2003/Jun W2
4	9: Business & Industry(R)_Jul/1994-2003/Jun 17
1	15: ABI/Inform(R)_1971-2003/Jun 18
127	16: Gale Group PROMT(R)_1990-2003/Jun 18
3	18: Gale Group F&S Index(R)_1988-2003/Jun 18
2	19: Chem.Industry Notes_1974-2003/ISS 200324
78	20: Dialog Global Reporter_1997-2003/Jun 18
19	34: SciSearch(R) Cited Ref Sci_1990-2003/Jun W2
3	35: Dissertation Abs Online_1861-2003/May
2	42: Pharmaceuticl News Idx_1974-2003/Jun W2
2	47: Gale Group Magazine DB(TM)_1959-2003/Jun 13
1	50: CAB Abstracts_1972-2003/May
3	63: Transport Res(TRIS)_1970-2003/May
12	71: ELSEVIER BIOBASE_1994-2003/Jun W3
14	73: EMBASE_1974-2003/Jun W2
1	94: JICST-EPlus_1985-2003/Jun W3
3	98: General Sci Abs/Full-Text_1984-2003/May
1	99: Wilson Appl. Sci & Tech Abs_1983-2003/May
341	103: Energy SciTec_1974-2003/May B2
Examined 50 files	
2	107: Adis R&D Insight_1986-2003/Jun W2
65	109: Nuclear Sci. Abs._1948-1976
1	111: TGG Natl.Newspaper Index(SM)_1979-2003/Jun 13
3	118: ICONDA-Intl Construction_1976-2003/Jun
1	128: PHARMAPROJECTS_1980-2003/Jun W2
2	129: PHIND(Archival)_1980-2003/Jun W2
5	135: NewsRx Weekly Reports_1995-2003/Jun W2
1	143: Biol. & Agric. Index_1983-2003/May
19	144: Pascal_1973-2003/Jun W1
109	148: Gale Group Trade & Industry DB_1976-2003/Jun 17
1	149: TGG Health&Wellness DB(SM)_1976-2003/Jun W2
15	155: MEDLINE(R)_1966-2003/Jun W2
6	156: ToxFile_1965-2003/Jun W3
1	158: DIOGENES(R)_1976-2003/Jun W3
1	162: Global Health_1983-2003/May
2	172: EMBASE Alert_2003/Jun W3
10	180: Federal Register_1985-2003/Jun 18
1	189: NDA Pipeline: New Drugs_1991-2003/Jun
1	203: AGRIS_1974-2003/May
2	211: Gale Group Newsearch(TM)_2003/Jun 17
Examined 100 files	
7	225: DIALOG(R):Domain Names
3	266: FEDRIP_2003/Apr
1	275: Gale Group Computer DB(TM)_1983-2003/Jun 18
1	315: ChemEng & Biotec Abs_1970-2003/May
2	319: Chem Bus NewsBase_1984-2003/Jun 18
3	340: CLAIMS(R)/US Patent_1950-03/Jun 17
1	342: Derwent Patents Citation Indx_1978-01/200310
2	348: EUROPEAN PATENTS_1978-2003/Jun W01
24	349: PCT FULLTEXT_1979-2002/UB=20030612,UT=20030605
1	357: Derwent Biotech Res.__1982-2003/Jun W4
Examined 150 files	
1	358: Current BioTech Abs_1983-2003/May
8	398: CHEMSEARCH(TM)_1957-2003/MAY
23	399: CA SEARCH(R)_1967-2003/UD=13825
1	429: Adis Newsletters(Archive)_1982-2003/Jun 18
12	434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
25	440: Current Contents Search(R)_1990-2003/Jun 18
2	441: ESPICOM Pharm&Med DEVICE NEWS_2003/Jun W3
3	445: IMS R&D Focus_1991-2003/Jun W1
1	452: Drug Data Report_1992-2003/May

```
          1   455: Drug News & Perspectives_1992-2003/May
          1   459: Daily Essentials (Archival)_1996-2003/Jun W2
  Examined 200 files
        232   545: Investext(R)_1982-2003/Jun 18
          1   570: Gale Group MARS(R)_1984-2003/Jun 18
          2   608: KR/T Bus.News._1992-2003/Jun 18
         65   610: Business Wire_1999-2003/Jun 18
          7   613: PR Newswire_1999-2003/Jun 18
        110   621: Gale Group New Prod.Annou.(R)_1985-2003/Jun 17
          9   624: McGraw-Hill Publications_1985-2003/Jun 17
          5   635: Business Dateline(R)_1985-2003/Jun 18
         20   636: Gale Group Newsletter DB(TM)_1987-2003/Jun 16
          2   646: Consumer Reports_1982-2003/May
        110   649: Gale Group Newswire ASAP(TM)_2003/Jun 16
         12   654: US PAT.FULL._1976-2003/Jun 17
  Examined 250 files
          2   745: Investext(R) PDF Index_1999--2003/Jun W3
          2   761: Datamonitor Market Res._1992-2003/Jun
          2   764: BCC Market Research_1989-2003/Jun
         32   810: Business Wire_1986-1999/Feb 28
         65   813: PR Newswire_1987-1999/Apr 30

80 files have one or more items; file list includes 281 files.

ave temp
p SearchSave "TD270" stored
f
r last SELECT statement was:
S PCRV

        Items   File
        -----   ----
          341   103: Energy SciTec_1974-2003/May B2
          232   545: Investext(R)_1982-2003/Jun 18
          174     6: NTIS_1964-2003/Jun W3
          127    16: Gale Group PROMT(R)_1990-2003/Jun 18
          110   621: Gale Group New Prod.Annou.(R)_1985-2003/Jun 17
          110   649: Gale Group Newswire ASAP(TM)_2003/Jun 16
          109   148: Gale Group Trade & Industry DB_1976-2003/Jun 17
          105     8: Ei Compendex(R)_1970-2003/Jun W2
           88     2: INSPEC_1969-2003/Jun W2
           78    20: Dialog Global Reporter_1997-2003/Jun 18
80 files have one or more items; file list includes 281 files.

      - Enter P or PAGE for more -

p
ur last SELECT statement was:
S PCRV

f       Items   File
-       -----   ----
1          65   109: Nuclear Sci. Abs._1948-1976
2          65   610: Business Wire_1999-2003/Jun 18
3          65   813: PR Newswire_1987-1999/Apr 30
4          32   810: Business Wire_1986-1999/Feb 28
5          25   440: Current Contents Search(R)_1990-2003/Jun 18
6          24   349: PCT FULLTEXT_1979-2002/UB=20030612,UT=20030605
7          23   399: CA SEARCH(R)_1967-2003/UD=13825
8          20     5: Biosis Previews(R)_1969-2003/Jun W2
9          20   636: Gale Group Newsletter DB(TM)_1987-2003/Jun 16
0          19    34: SciSearch(R) Cited Ref Sci_1990-2003/Jun W2
80 files have one or more items; file list includes 281 files.

      - Enter P or PAGE for more -

p
ur last SELECT statement was:
S PCRV

f       Items   File
```

```
        -----   ----
           19   144: Pascal_1973-2003/Jun W1
           15   155: MEDLINE(R)_1966-2003/Jun W2
           14    73: EMBASE_1974-2003/Jun W2
           12    71: ELSEVIER BIOBASE_1994-2003/Jun W3
           12   434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
           12   654: US PAT.FULL._1976-2003/Jun 17
           10   180: Federal Register_1985-2003/Jun 18
            9   624: McGraw-Hill Publications_1985-2003/Jun 17
            8   398: CHEMSEARCH(TM)_1957-2003/MAY
            7   225: DIALOG(R):Domain Names
 80 files have one or more items; file list includes 281 files.

      - Enter P or PAGE for more -
```

```
ur last SELECT statement was:
 S PCRV

        Items   File
        -----   ----
            7   613: PR Newswire_1999-2003/Jun 18
            6   156: ToxFile_1965-2003/Jun W3
            5   135: NewsRx Weekly Reports_1995-2003/Jun W2
            5   635: Business Dateline(R)_1985-2003/Jun 18
            4     9: Business & Industry(R)_Jul/1994-2003/Jun 17
            3    18: Gale Group F&S Index(R)_1988-2003/Jun 18
            3    35: Dissertation Abs Online_1861-2003/May
            3    63: Transport Res(TRIS)_1970-2003/May
            3    98: General Sci Abs/Full-Text_1984-2003/May
            3   118: ICONDA-Intl Construction_1976-2003/Jun
 80 files have one or more items; file list includes 281 files.

      - Enter P or PAGE for more -

ur last SELECT statement was:
 S PCRV

        Items   File
        -----   ----
            3   266: FEDRIP_2003/Apr
            3   340: CLAIMS(R)/US Patent_1950-03/Jun 17
            3   445: IMS R&D Focus_1991-2003/Jun W1
            2    19: Chem.Industry Notes_1974-2003/ISS 200324
            2    42: Pharmaceuticl News Idx_1974-2003/Jun W2
            2    47: Gale Group Magazine DB(TM)_1959-2003/Jun 13
            2   107: Adis R&D Insight_1986-2003/Jun W2
            2   129: PHIND(Archival)_1980-2003/Jun W2
            2   172: EMBASE Alert_2003/Jun W3
            2   211: Gale Group Newsearch(TM)_2003/Jun 17
 80 files have one or more items; file list includes 281 files.

      - Enter P or PAGE for more -

ur last SELECT statement was:
 S PCRV

        Items   File
        -----   ----
            2   319: Chem Bus NewsBase_1984-2003/Jun 18
            2   348: EUROPEAN PATENTS_1978-2003/Jun W01
            2   441: ESPICOM Pharm&Med DEVICE NEWS_2003/Jun W3
            2   608: KR/T Bus.News._1992-2003/Jun 18
            2   646: Consumer Reports_1982-2003/May
            2   745: Investext(R) PDF Index_1999--2003/Jun W3
            2   761: Datamonitor Market Res._1992-2003/Jun
            2   764: BCC Market Research_1989-2003/Jun
            1    15: ABI/Inform(R)_1971-2003/Jun 18
            1    50: CAB Abstracts_1972-2003/May
 80 files have one or more items; file list includes 281 files.
```

```
      - Enter P or PAGE for more -
p
ur last SELECT statement was:
 S PCRV

f         Items   File
-         -----   ----
1             1    94: JICST-EPlus_1985-2003/Jun W3
2             1    99: Wilson Appl. Sci & Tech Abs_1983-2003/May
3             1   111: TGG Natl.Newspaper Index(SM)_1979-2003/Jun 13
4             1   128: PHARMAPROJECTS_1980-2003/Jun W2
5             1   143: Biol. & Agric. Index_1983-2003/May
6             1   149: TGG Health&Wellness DB(SM)_1976-2003/Jun W2
7             1   158: DIOGENES(R)_1976-2003/Jun W3
8             1   162: Global Health_1983-2003/May
9             1   189: NDA Pipeline: New Drugs_1991-2003/Jun
0             1   203: AGRIS_1974-2003/May
 80 files have one or more items; file list includes 281 files.

      - Enter P or PAGE for more -
b n1-n60;exs
     18jun03 10:54:02 User228210 Session D348.3
          $2.09    1.043 DialUnits File411
   $2.09  Estimated cost File411
   $0.22  TELNET
   $2.31  Estimated cost this search
   $2.32  Estimated total session cost   1.267 DialUnits

STEM:OS  - DIALOG OneSearch
File 103:Energy SciTec  1974-2003/May B2
       (c) 2003 Contains copyrighted material
ile 103: For access restrictions see Help Restrict.
File 545:Investext(R)  1982-2003/Jun 18
       (c) 2003 Thomson Financial Networks
File   6:NTIS  1964-2003/Jun W3
       (c) 2003 NTIS, Intl Cpyrght All Rights Res
ile   6: Alert feature enhanced for multiple files, duplicates
moval, customized scheduling. See HELP ALERT.
File  16:Gale Group PROMT(R)  1990-2003/Jun 18
       (c) 2003 The Gale Group
ile  16: Alert feature enhanced for multiple files, duplicate
moval, customized scheduling. See HELP ALERT.
File 621:Gale Group New Prod.Annou.(R)  1985-2003/Jun 17
       (c) 2003 The Gale Group
File 649:Gale Group Newswire ASAP(TM)  2003/Jun 16
       (c) 2003 The Gale Group
File 148:Gale Group Trade & Industry DB  1976-2003/Jun 17
       (c)2003 The Gale Group
ile 148: Alert feature enhanced for multiple files, duplicate
moval, customized scheduling. See HELP ALERT.
File   8:Ei Compendex(R)  1970-2003/Jun W2
       (c) 2003 Elsevier Eng.  Info. Inc.
ile   8: Alert feature enhanced for multiple files, duplicates
moval, customized scheduling. See HELP ALERT.
File   2:INSPEC  1969-2003/Jun W2
       (c) 2003 Institution of Electrical Engineers
ile   2: Alert feature enhanced for multiple files, duplicates
moval, customized scheduling. See HELP ALERT.
File  20:Dialog Global Reporter  1997-2003/Jun 18
       (c) 2003 The Dialog Corp.
File 109:Nuclear Sci. Abs.  1948-1976
       (c)1997 Contains copyrighted material
File 109: For access restrictions, see HELP RESTRIC1.
File 610:Business Wire  1999-2003/Jun 18
       (c) 2003 Business Wire.
ile 610: File 610 now contains data from 3/99 forward.
chive data (1986-2/99) is available in File 810.
File 813:PR Newswire  1987-1999/Apr 30
```

(c) 1999 PR Newswire Association Inc
File 810:Business Wire 1986-1999/Feb 28
(c) 1999 Business Wire
File 440:Current Contents Search(R) 1990-2003/Jun 18
(c) 2003 Inst for Sci Info
File 349:PCT FULLTEXT 1979-2002/UB=20030612,UT=20030605
(c) 2003 WIPO/Univentio
File 399:CA SEARCH(R) 1967-2003/UD=13825
(c) 2003 American Chemical Society
ile 399: Use is subject to the terms of your user/customer agreement.
ert feature enhanced for multiple files, etc. See HELP ALERT.
File 5:Biosis Previews(R) 1969-2003/Jun W2
(c) 2003 BIOSIS
File 636:Gale Group Newsletter DB(TM) 1987-2003/Jun 16
(c) 2003 The Gale Group
File 34:SciSearch(R) Cited Ref Sci 1990-2003/Jun W2
(c) 2003 Inst for Sci Info
File 144:Pascal 1973-2003/Jun W1
(c) 2003 INIST/CNRS
File 155:MEDLINE(R) 1966-2003/Jun W2
(c) format only 2003 The Dialog Corp.
ile 155: Medline has been reloaded and accession numbers have
anged. Please see HELP NEWS 155.
File 73:EMBASE 1974-2003/Jun W2
(c) 2003 Elsevier Science B.V.
ile 73: Alert feature enhanced for multiple files, duplicates
moval, customized scheduling. See HELP ALERT.
File 71:ELSEVIER BIOBASE 1994-2003/Jun W3
(c) 2003 Elsevier Science B.V.
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info
File 654:US PAT.FULL. 1976-2003/Jun 17
(c) FORMAT ONLY 2003 THE DIALOG CORP.
ile 654: Reassignments current through Feb. 7, 2003
File 180:Federal Register 1985-2003/Jun 18
(c) 2003 format only The DIALOG Corp
File 624:McGraw-Hill Publications 1985-2003/Jun 17
(c) 2003 McGraw-Hill Co. Inc
ile 624: Homeland Security & Defense and 9 Platt energy journals added
ease see HELP NEWS624 for more
File 398:CHEMSEARCH(TM) 1957-2003/MAY
(c) 2003 AMER.CHEM.SOC.
ile 398: Use is subject to the terms of your user/customer agreement.
roblems with SORT. RANK charge added. See HELP RATES 398.
File 225:DIALOG(R):Domain Names (c) 2003 Dialog & SnapNames.
ile 225: See HELP NEWS225 for information on changes to search prefixes
d new display codes
File 613:PR Newswire 1999-2003/Jun 18
(c) 2003 PR Newswire Association Inc
ile 613: File 613 now contains data from 5/99 forward.
rchive data (1987-4/99) is available in File 813.
File 156:ToxFile 1965-2003/Jun W3
(c) format only 2003 The Dialog Corporation
ile 156: ToxFile has been reloaded. Accession numbers
ve changed. Please see HELP NEWS 156 for details.
File 135:NewsRx Weekly Reports 1995-2003/Jun W2
(c) 2003 NewsRx
ile 135: New newsletters are now added. See Help News135 for the
mplete list of newsletters.
File 635:Business Dateline(R) 1985-2003/Jun 18
(c) 2003 ProQuest Info&Learning
File 9:Business & Industry(R) Jul/1994-2003/Jun 17
(c) 2003 Resp. DB Svcs.
File 18:Gale Group F&S Index(R) 1988-2003/Jun 18
(c) 2003 The Gale Group
File 35:Dissertation Abs Online 1861-2003/May
(c) 2003 ProQuest Info&Learning
File 63:Transport Res(TRIS) 1970-2003/May
(c) fmt only 2003 Dialog Corp.

```
File  98:General Sci Abs/Full-Text 1984-2003/May
       (c) 2003 The HW Wilson Co.
File 118:ICONDA-Intl Construction  1976-2003/Jun
       (c) 2003 Fraunhofer-IRB
File 266:FEDRIP  2003/Apr
       Comp & dist by NTIS, Intl Copyright All Rights Res
File 340:CLAIMS(R)/US Patent  1950-03/Jun 17
       (c) 2003 IFI/CLAIMS(R)
le 340: The Claims U.S. Patent databases have been reloaded.
ELP NEWS340 & HELP ALERTS340 for search, display & Alert info.
File 445:IMS R&D Focus  1991-2003/Jun W1
       (c) 2003 IMS Health & Affiliates
File  19:Chem.Industry Notes  1974-2003/ISS 200324
       (c) 2003 Amer.Chem.Soc.
le  19: Use is subject to the terms of your user/customer agreement.
ert feature enhanced for multiple files, etc. See HELP ALERT.
File  42:Pharmaceuticl News Idx  1974-2003/Jun W2
       (c)2003 ProQuest Info&Learning
File  47:Gale Group Magazine DB(TM)  1959-2003/Jun 13
       (c) 2003 The Gale group
File 107:Adis R&D Insight  1986-2003/Jun W2
       (c) 2003 Adis Data Information BV.
File 129:PHIND(Archival)  1980-2003/Jun W2
       (c) 2003 PJB Publications, Ltd.
File 172:EMBASE Alert  2003/Jun W3
       (c) 2003 Elsevier Science B.V.
File 211:Gale Group Newsearch(TM)  2003/Jun 17
       (c) 2003 The Gale Group
File 319:Chem Bus NewsBase  1984-2003/Jun 18
       (c) 2003 Elsevier Eng. Info. Inc.
ile 319: Alert feature enhanced for multiple files, duplicate
moval, customized scheduling. See HELP ALERT.
File 348:EUROPEAN PATENTS  1978-2003/Jun W01
       (c) 2003 European Patent Office
File 441:ESPICOM Pharm&Med DEVICE NEWS  2003/Jun W3
       (c) 2003 ESPICOM Bus.Intell.
File 608:KR/T Bus.News.  1992-2003/Jun 18
       (c)2003 Knight Ridder/Tribune Bus News
File 646:Consumer Reports  1982-2003/May
       (c) 2003 Consumer Union
File 745:Investext(R) PDF Index  1999--2003/Jun W3
       (c)2003 Thomson Fin. Networks
ile 745: INVESTEXT NOW ON DIALOGWEB
TER HELP NEWS745 FOR MORE
File 761:Datamonitor Market Res.  1992-2003/Jun
       (c) 2003 Datamonitor
File 764:BCC Market Research  1989-2003/Jun
       (c) 2003 Business Communication Co.
ile 764: KWIC costs $3.30 in File 764.
File  15:ABI/Inform(R)  1971-2003/Jun 18
       (c) 2003 ProQuest Info&Learning
File  15: Alert feature enhanced for multiple files, duplicate
moval, customized scheduling. See HELP ALERT.
File  50:CAB Abstracts  1972-2003/May
       (c) 2003 CAB International
File  50: Truncating CC codes is recommended for full retrieval.
e Help News50 for details.

     Set  Items  Description
     ---  -----  -----------
ecuting TD270
light option is not available in file(s) 19, 109, 398, 399
LIGHT set on as '%'
     S1    2033  PCRV
s s1 and pseudomonas
          2033  S1
        520782  PSEUDOMONAS
     S2     223  S1 AND PSEUDOMONAS
s s2 and protein
```

```
        223  S2
   11062652  PROTEIN
 S3     175  S2 AND PROTEIN
s3 and antibody or antibodies
essing
essed  20 of  60 files ...
leted processing all files
        175  S3
    2445490  ANTIBODY
    2287070  ANTIBODIES
 S4 2287108  S3 AND ANTIBODY OR ANTIBODIES
s4 and s3
    2287108  S4
        175  S3
 S5     122  S4 AND S3

Duplicate detection is not supported for File 349.
Duplicate detection is not supported for File 654.
Duplicate detection is not supported for File 398.
Duplicate detection is not supported for File 225.
Duplicate detection is not supported for File 340.
Duplicate detection is not supported for File 19.
Duplicate detection is not supported for File 107.
Duplicate detection is not supported for File 348.
Duplicate detection is not supported for File 441.
Duplicate detection is not supported for File 761.
Duplicate detection is not supported for File 764.

Records from unsupported files will be retained in the RD set.
Record 440:15927493 ignored; incomplete bibliographic data, not retained
 RD set
Record 440:13242482 ignored; incomplete bibliographic data, not retained
 RD set
Record 440:12995370 ignored; incomplete bibliographic data, not retained
 RD set
examined 50 records  (50)
examined 50 records  (100)
Record 441:34236 ignored; incomplete bibliographic data, not retained in
 set
Record 441:32012 ignored; incomplete bibliographic data, not retained in
 set
completed examining records
    S6      61  RD (unique items)
ds

t      Items   Description
        2033   PCRV
         223   S1 AND PSEUDOMONAS
         175   S2 AND PROTEIN
     2287108   S3 AND ANTIBODY OR ANTIBODIES
         122   S4 AND S3
          61   RD (unique items)
t s6/3,ab/1-30
>No matching display code(s) found in file(s): 107, 129, 135, 180, 225,
 398, 441, 608, 624, 635, 761, 764, 810, 813

5/3,AB/1     (Item 1 from file: 545)
IALOG(R)File 545:Investext(R)
c) 2003 Thomson Financial Networks . All rts. reserv.

1587808
NTERMUNE PHARMACEUTICALS
EHENY, A.R.
EW YORK (STATE OF)
EHMAN  BROTHERS, INC. (DATE: February 21, 01)  (Report Number: 2480630)PAGE
 OF 3,  TEXT PAGE
his is a(n) COMPANY report.
```

,AB/2 (Item 2 from file: 545)
OG(R)File 545:Investext(R)
2003 Thomson Financial Networks . All rts. reserv.

9462
TEIN% DESIGN LABS
EK, J.D.
YORK (STATE OF)
RD FRERES & COMPANY, LLC (DATE: November 29, 00) (Report Number:
C646)PAGE 1 OF 2, TEXT/TABLE PAGE
s is a(n) COMPANY report.

3,AB/3 (Item 3 from file: 545)
LOG(R)File 545:Investext(R)
2003 Thomson Financial Networks . All rts. reserv.

33939
OTEIN% DESIGN LABS/INTERMUNE
D, M.
YORK (STATE OF)
MAN BROTHERS, INC. (DATE: November 29, 00) (Report Number: 2384611)PAGE
F 2, TEXT PAGE
s is a(n) COMPANY report.

3,AB/4 (Item 4 from file: 545)
LOG(R)File 545:Investext(R)
2003 Thomson Financial Networks . All rts. reserv.

21331
ERMUNE PHARMACEUTICALS: INITIATING COVERAGE
ENY, A.R.
YORK (STATE OF)
MAN BROTHERS, INC. (DATE: August 2, 00) (Report Number: 2243254)PAGE 7
15, TEXT PAGE
s is a(n) COMPANY report.

/3,AB/5 (Item 5 from file: 545)
ALOG(R)File 545:Investext(R)
2003 Thomson Financial Networks . All rts. reserv.

744719
TERMUNE PHARMACEUTICALS
LLOY, M.
W YORK (STATE OF)
ASE HAMBRECHT & QUIST INC. (DATE: June 13, 00) (Report Number: 2192983)
GE 10 OF 16, TEXT PAGE
is is a(n) COMPANY report.

/3,AB/6 (Item 1 from file: 16)
ALOG(R)File 16:Gale Group PROMT(R)
) 2003 The Gale Group. All rts. reserv.

282537 Supplier Number: 80767850
terMune Announces Five Abstracts to Be Presented at ICAAC Annual Meeting
Highlighting Infectious Disease Pipeline; Phase III Oritavancin Results
in CSSI and Phase II Actimmune Results in Fungal Infections to Be
Presented as Late-Breakers.
Newswire, pSFTH02613122001
c 13, 2001
nguage: English Record Type: Fulltext
cument Type: Newswire; Trade
rd Count: 810

/3,AB/7 (Item 2 from file: 16)

OG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

2686 Supplier Number: 79398132
rMune Announces Third Quarter 2001 Financial Results.
ewswire, pNA
24, 2001
uage: English Record Type: Fulltext
ment Type: Newswire; Trade
Count: 1421

,AB/8 (Item 3 from file: 16)
LOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

59452 Supplier Number: 79083290
erMune Carries Forward Work On MAb Compound.
& Outbreaks Week, pNA
2, 2001
guage: English Record Type: Fulltext
ument Type: Newsletter; Professional
d Count: 454

3,AB/9 (Item 4 from file: 16)
LOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

61634 Supplier Number: 79023138
tibody% Drug for %Pseudomonas% Infection.
lied Genetics News, v22, n2, pNA
t, 2001
guage: English Record Type: Fulltext
ument Type: Newsletter; Trade
rd Count: 429

/3,AB/10 (Item 5 from file: 16)
ALOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

951655 Supplier Number: 77710441
terMune accepts %antibody% from %Protein% Design Labs.(Brief Article)
rketletter, pNA
pt 3, 2001
nguage: English Record Type: Fulltext
ticle Type: Brief Article
cument Type: Newsletter; Trade
rd Count: 78

/3,AB/11 (Item 6 from file: 16)
ALOG(R)File 16:Gale Group PROMT(R)
) 2003 The Gale Group. All rts. reserv.

3931960 Supplier Number: 77480563
Ab, %Pseudomonas% aeruginosa, InterMune InterMune, %Protein% Design
receives humanized MAb.(Brief Article)
& D Focus Drug News, pNA
ugust 27, 2001
anguage: English Record Type: Fulltext
rticle Type: Brief Article
ocument Type: Magazine/Journal; Trade
ord Count: 114

6/3,AB/12 (Item 7 from file: 16)
IALOG(R)File 16:Gale Group PROMT(R)

003 The Gale Group. All rts. rese .

301 Supplier Number: 77245082
Mune to Develop Compound for the Treatment and Prevention of
eudomonas% Infections.
wswire, p0834
t 16, 2001
age: English Record Type: Fulltext
ent Type: Newswire; Trade
Count: 797

,AB/13 (Item 8 from file: 16)
OG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

6245 Supplier Number: 68016518
%Pseudomonas% aeruginosa, InterMune InterMune, %Protein% Design
censing agreement.
D Focus Drug News, pNA
18, 2000
uage: English Record Type: Fulltext
ment Type: Magazine/Journal; Trade
Count: 137

,AB/14 (Item 9 from file: 16)
LOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

91204 Supplier Number: 67460930
otein% Design Labs and InterMune Announce %Antibody% Humanization
greement.
Newswire, pNA
28, 2000
guage: English Record Type: Fulltext
ument Type: Newswire; Trade
d Count: 563

3,AB/15 (Item 10 from file: 16)
ALOG(R)File 16:Gale Group PROMT(R)
2003 The Gale Group. All rts. reserv.

960444 Supplier Number: 66520548
eventing %Pseudomonas%- Induced Pneumonia.
plied Genetics News, v21, n3, pNA
, 2000
nguage: English Record Type: Fulltext
cument Type: Newsletter; Trade
rd Count: 280

/3,AB/16 (Item 11 from file: 16)
ALOG(R)File 16:Gale Group PROMT(R)
) 2003 The Gale Group. All rts. reserv.

812514 Supplier Number: 65268780
AAC Abstract Reports Therapy With %Antibody% To %PcrV% Effective Against
%Pseudomonas% Aeruginosa Pneumonia.
siness Wire, p2081
ept 18, 2000
anguage: English Record Type: Fulltext
ocument Type: Newswire; Trade
ord Count: 659

6/3,AB/17 (Item 12 from file: 16)
IALOG(R)File 16:Gale Group PROMT(R)

ilwaukee, WI 53202, US,
t and Priority Information (Country, Number, Date):
ent: WO 200264161 A2-A3 20020822 (WO 0264161)
lication: WO 2002US2382 20020125 (PCT/WO US0202382)
ority Application: US 2001770916 20010126; US 2001264795 20010129
nated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO
SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
P) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
A) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
P) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
A) AM AZ BY KG KZ MD RU TJ TM
ication Language: English
ng Language: English
text Word Count: 10010

ish Abstract
method of inhibiting, moderating or diagnosing %Pseudomonas% aeruginosa
fection is disclosed. In one embodiment, this method comprises
oculating a patient with an effective amount of %PcrV% antigen.

ch Abstract
invention concerne un procede d'inhibition, de moderation ou de
agnostic d'infection a %Pseudomonas% aeruginosa. Dans une realisation,
procede consiste a inoculer un patient avec une quantite efficace
antigene %PcrV%.

3,AB/22 (Item 2 from file: 349)
LOG(R)File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

29955
CINE COMPOSITION
POSITION VACCINALE
ent Applicant/Assignee:
MITHKLINE BEECHAM BIOLOGICALS S A, Rue de l'Institut 89, B-1330
Rixensart, BE, BE (Residence), BE (Nationality), (For all designated
states except: US)
ent Applicant/Inventor:
ERTHET Francois-Xavier Jacques, GlaxoSmithKline Biologicals S.A., Rue de
l'Institute 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)
OBET Yves, GlaxoSmithKline Biologicals S.A., Rue de l'Institute 89,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
OOLMAN Jan, GlaxoSmithKline Biologicals S.A., Rue de l'Institute 89,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
VERLANT Vincent Georges Christian Louis, GlaxoSmithKline Biologicals
S.A., Rue de l'Institute 89, B-1330 Rixensart, BE, BE (Residence), BE
(Nationality), (Designated only for: US)
gal Representative:
LUBIENSKI Michael John (agent), GlaxoSmithKline CN925.1, Corporate
Intellectual Property, 980 Great West Road, Brentford, Middlesex TW8
9GS, GB,
tent and Priority Information (Country, Number, Date):
Patent: WO 200262380 A2 20020815 (WO 0262380)
Application: WO 2002EP1356 20020208 (PCT/WO EP0201356)
Priority Application: GB 20013169 20010208
signated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO
RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

cation Language: English
g Language: English
ext Word Count: 13939

sh Abstract
e present invention relates to the field of Gram-negative bacterial
ccine compositions, their manufacture, and the use of such compositions
medicine. More particularly it relates to the field of useful
am-negative bacterial outer membrane vesicle (or bleb) compositions
mprising heterologously expressed Chlamydia antigens, and advantageous
thods of rendering these compositions more effective and safer as a
ccine.

ch Abstract
invention concerne des compositions vaccinales a base de bacteries a
am negatif, leur preparation, ainsi que leur utilisation en medecine.
us particulierement, l'invention concerne des compositions utiles de
sicules de membranes externes (bleb) de bacteries a gram negatif
esentant une expression d'antigenes deChlamydia heterologues, ainsi que
s methodes avantageuses permettant de rendre ces compositions plus
fficaces et plus sures comme vaccins.

3,AB/23 (Item 3 from file: 349)
LOG(R)File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

29953
ERBLEBBING BACTERIAL STRAINS AND USE THEREOF FOR PRODUCTION OF VACCINES
POSITION DE VACCIN
ent Applicant/Assignee:
MITHKLINE BEECHAM BIOLOGICALS S A, Rue de l'Institut 89, B-1330
Rixensart, BE, BE (Residence), BE (Nationality), (For all designated
states except: US)
ent Applicant/Inventor:
ERTHET Francois-Xavier Jacques, GlaxoSmithKline Biologicals s.a., Rue de
l'Institut 89, B-1330 Rixensart, BE, BE (Residence), FR (Nationality),
(Designated only for: US)
ENOEL PHilippe, GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
NEYT Cecile Anne, GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
POOLMAN Jan, GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89,
B-1330 Rixensart, BE, BE (Residence), NL (Nationality), (Designated
only for: US)
THONNARD Joelle, GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
gal Representative:
LUBIENSKI Michael John (agent), Corporate Intellectual Property,
GlaxoSmithKline Beecham CN925.1, 980 Great West Road, Brentford,
Middlesex TW8 9GS, GB,
atent and Priority Information (Country, Number, Date):
Patent: WO 200262378 A2-A3 20020815 (WO 0262378)
Application: WO 2002EP1361 20020208 (PCT/WO EP0201361)
Priority Application: GB 20013171 20010208
esignated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO
RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
ublication Language: English
iling Language: English
ulltext Word Count: 14322

lish Abstract
ne present invention relates to the field genetically-engineered
ram-negative bacterial strains that have improved outer-membrane vesicle
nedding properties, and vaccine compositions comprising these bacteria
r vesicles. The present invention provides a hyperbledding Gram-negative
acterium which has been genetically modified by either or both processes
elected from a group of consisting of: down-regulation of expression of
ne or more tol genes; and mutation of one or more gene(s) encoding a
protein% comprising a peptidoglycan-associated site to attenuate the
eptidoglycan binding activity of the %protein%(s).

nch Abstract
a presente invention concerne le domaine des nouvelles souches de
acteries Gram negatif fabriquees qui presentent des proprietes
meliorees d'elimination des vesicules de la membrane exterieure et des
ompositions de vaccin comprenant ces bacteries ou ces vesicules. Cette
nvention concerne une bacterie gram negatif hyperboursouflee qui a ete
enetiquement modifiee par un et/ou deux processus tels que: la
egulation restrictive de l'expression d'au moins un gene tol; et
a mutation d'au moins un gene codant une proteine comprenant un site
ssocie au peptidoglycane pour attenuer l'activite de liaison avec le
eptidoglycane de la (des) proteine(s).

3,AB/24 (Item 4 from file: 349)
LOG(R)File 349:PCT FULLTEXT

877369
CCINES COMPRISING OUTER MEMBRANE VESCILES FROM GRAM NEGATIVE BACTERIA
MPOSITION VACCINALE
tent Applicant/Assignee:
SMITHKLINE BEECHAM BIOLOGICALS S A, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (For all designated states except: US)
tent Applicant/Inventor:
BERTHET Francois-Xavier Jacques, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), FR (Nationality), (Designated only for: US)
DALEMANS Wilfried, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)
DENOEL Philippe, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)
DEQUESNE Guy, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)
FERON Christiane, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)
GARCON Nathalie, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), FR (Nationality), (Designated only for: US)
LOBET Yves, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)
POOLMAN Jan, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), NL (Nationality), (Designated only for: US)
THIRY Georges, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)
THONNARD Joelle, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)
VOET Pierre, GlaxoSmithKline Beecham Biologicals, Rue de l'Institut 89, B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated only for: US)

gal Representative:
LUBIENSKI Michael John (agent), SmithKline Beecham, Corporate
Intellectual Property (CN9.25.1), 980 Great West Road, Brentford,
Middlesex TW8 9GS, GB,
tent and Priority Information (Country, Number, Date):
Patent: WO 200209746 A2-A3 20020207 (WO 0209746)
Application: WO 2001EP8857 20010731 (PCT/WO EP0108857)
Priority Application: WO 2000EP7424 20000731; GB 20013170 20010208
signated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
blication Language: English
ling Language: English
lltext Word Count: 32856

glish Abstract
The present invention relates to the field of vaccine formulation,
particularly the field of novel adjuvant compositions comprising outer
membrane vesicles (or blebs), and advantageous methods of detoxifying
these compositions, and advantageous methods of use of such adjuvants.

ench Abstract
Cette invention, qui a trait au domaine de la formulation vaccinale,
notamment a de nouvelles compositions d'adjuvant comportant des vesicule
a membrane externe (ou bulles), concerne egalement des methodes
permettant de detoxiquer avantageusement ces compositions ainsi que des
methodes d'utilisation avantageuse des adjuvants susmentionnes.

/3,AB/25 (Item 5 from file: 349)
ALOG(R)File 349:PCT FULLTEXT
) 2003 WIPO/Univentio. All rts. reserv.

804134
COMBINANT CHLAMYDIA VACCINE
CCINS RECOMBINES CONTRE LES CHLAMYDIA
tent Applicant/Assignee:
MICHIGAN STATE UNIVERSITY, 238 Administration Building, East Lansing, MI
48824, US, US (Residence), US (Nationality)
ventor(s):
BRUBAKER Robert R, 11042 W. Scipio Highway, Vermontville, MI 49096, US,
MOTIN Vladimir L, 5621 Charlotte Way, #17, Livermore, CA 94550, US,
gal Representative:
McLEOD Ian C (agent), 2190 Commons Parkway, Okemos, MI 48864, US,
tent and Priority Information (Country, Number, Date):
Patent: WO 200135992 A1 20010525 (WO 0135992)
Application: WO 2000US30876 20001110 (PCT/WO US0030876)
Priority Application: US 99444425 19991119
signated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
UA UG UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
blication Language: English
ling Language: English
lltext Word Count: 14526

glish Abstract
The present invention provides vaccines and methods for making the
vaccines that actively or passively protect a human or animal against
Chlamydia infection. In particular, the present invention provides a

ccine that provides active immunity which comprises a polypeptide o
A vaccine that contains or expresses at least one epitope of
lypeptide that has an amino acid sequence that is substantially similar
an amino acid sequence of a polypeptide encoded by open reading frame
863 of Chlamydia trachomatis. The present invention further provides a
ccine that provides passive immunity to Chlamydia comprising polyclonal
monoclonal %antibodies% against at least one epitope of a polypeptide
coded by open reading frame CT863 of Chlamydia trachomatis. Further
ill, the present invention provides a method for preventing an
nflammatory reaction, in particular, in a skin graft, by providing a
olypeptide that is substantially similar to a polypeptide encoded by
pen reading frame CT863 of Chlamydia trachomatis.

nch Abstract

a presente invention concerne des vaccins et des methodes de production
es vaccins protegeant activement ou passivement un sujet humain ou
nimal contre une infection a Chlamydia. En particulier, la presente
nvention concerne un vaccin procurant une immunite active qui comprend
n vaccin polypeptidique ou a ADN contenant ou exprimant au moins un
pitope de polypeptide presentant une sequence d'acides amines
ensiblement similaire a une sequence d'acides amines d'un polypeptide
ode par un cadre de lecture ouvert CT863 de Chlamydia trachomatis. La
resente invention concerne egalement un vaccin procurant une immunite
assive contre les Chlamydia et comprenant des anticorps polyclonaux ou
onoclonaux contre au moins un epitope d'un polypeptide code par le cadre
e lecture ouvert CT863 de Chlamydia trachomatis. De plus, la presente
nvention concerne une methode de prevention d'une reaction
nflammatoire, en particulier, dans une greffe de peau, par l'obtention
'un polypeptide sensiblement similaire a un polypeptide code par le
adre de lecture ouvert CT863 de Chlamydia trachomatis.

3,AB/26 (Item 6 from file: 349)
LOG(R)File 349:PCT FULLTEXT
2003 WIPO/Univentio. All rts. reserv.

76938
NETICALLY ENGINEERED BLEB VACCINE
MPOSITION DE VACCIN
tent Applicant/Assignee:
SMITHKLINE BEECHAM BIOLOGICALS S A, 89, rue de l'Institut, B-1330
Rixensart, BE, BE (Residence), BE (Nationality), (For all designated
states except: US)
tent Applicant/Inventor:
BERTHET Francois-Xavier Jacques, SmithKline Beecham Biologicals s.a., 89,
rue de l'Institut, B-1330 Rixensart, BE, BE (Residence), FR
(Nationality), (Designated only for: US)
DALEMANS Wilfried L J, SmithKline Beecham Biologicals s.a., 89, rue de
l'Institut, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)
DENOEL Philippe, SmithKline Beecham Biologicals s.a., 89, rue de
l'Institut, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)
DEQUESNE Guy, SmithKline Beecham Biologicals s.a., 89, rue de l'Institut,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
FERON Christiane, SmithKline Beecham Biologicals s.a., 89, rue de
l'Institut, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)
LOBET Yves, SmithKline Beecham Biologicals s.a., 89, rue de l'Institut,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
POOLMAN Jan, SmithKline Beecham Biologicals s.a., 89, rue de l'Institut,
B-1330 Rixensart, BE, NL (Residence), NL (Nationality), (Designated
only for: US)
THIRY Georges, SmithKline Beecham Biologicals s.a., 89, rue de
l'Institut, B-1330 Rixensart, BE, BE (Residence), BE (Nationality),
(Designated only for: US)
THONNARD Joelle, SmithKline Beecham Biologicals s.a., 89, rue de

l'Institut, B-1330 Rixensart, BE, [redacted] (Residence), BE (Nationality), [redacted]
(Designated only for: US)
ET Pierre, SmithKline Beecham Biologicals s.a., 89, rue de l'Institut,
B-1330 Rixensart, BE, BE (Residence), BE (Nationality), (Designated
only for: US)
l Representative:
LTON Marcus Jonathan William (agent), Corporate Intellectual Property,
SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8
9EP, GB,
nt and Priority Information (Country, Number, Date):
tent: WO 200109350 A2-A3 20010208 (WO 0109350)
plication: WO 2000EP7424 20000731 (PCT/WO EP0007424)
iority Application: GB 9918319 19990803
gnated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
EA) AM AZ BY KG KZ MD RU TJ TM
lication Language: English
ing Language: English
ltext Word Count: 33458

lish Abstract
he present invention relates to an immuno-protective and non-toxic
ram-negative bleb vaccine suitable for paediatric use. Examples of the
ram-negative strains from which the blebs are made are N. meningitidis,
. catarrhalis and H. influenzae. The blebs of the invention are improved
y one or more genetic changes to the chromosome of the bacterium,
ncluding up-regulation of protective antigens, down-regulation of
mmunodominant non-protective antigens, and detoxification of the Lipid A
oiety of LPS.

nch Abstract
'invention concerne un vaccin immunoprotecteur et non toxique produit a
partir des bulles de la membrane externe (<= bleb >=), convenant pour les
pplications pediatriques. Les souches gram-negatives produisant ces
oulles comprennent par exemple N. meningitidis, M. catarrhalis et H.
nfluenzae. Ces vaccins sont ameliores au moyen d'une ou de plusieurs
odifications genetiques du chromosome de la bacterie, ces modifications
roduisant notamment une regulation positive des antigenes protecteurs et
ne regulation negative des antigenes non protecteurs immunodominants,
ainsi qu'une detoxication de la portion lipidique A des LPS.

/3,AB/27 (Item 7 from file: 349)
ALOG(R)File 349:PCT FULLTEXT

764867
HUMAN SECRETED PROTEINS
PROTEINES SECRETEES HUMAINES
tent Applicant/Assignee:
HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)
tent Applicant/Inventor:
ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality)
RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US,
US (Residence), US (Nationality), (Designated only for: US)
KOMATSOULIS George A, 9518 Garwood Street, Silver Spring, MD 20901, US,
US (Residence), US (Nationality), (Designated only for: US)
egal Representative:
HOOVER Kenley K (et al) (agent), Human Genome Sciences, Inc., 9410 Key
West Avenue, Rockville, MD 20850, US,
atent and Priority Information (Country, Number, Date):

tent: WO 200077026 A[redacted]0001221 (WO 0077026)
plication: WO 2000US14973 20000601 (PCT/WO US0014973)
iority Application: US 99138630 19990611
gnated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TR TT TZ UA UG US UZ VN YU ZA ZW
P) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
A) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
P) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
A) AM AZ BY KG KZ MD RU TJ TM
ication Language: English
ng Language: English
text Word Count: 153279

ish Abstract
he present invention relates to novel human secreted proteins and
solated nucleic acids containing the coding regions of the genes
ncoding such proteins. Also provided are vectors, host cells,
antibodies%, and recombinant methods for producing human secreted
roteins. The invention further relates to diagnostic and therapeutic
ethods useful for diagnosing and treating diseases, disorders, and/or
onditions related to these novel human secreted proteins.

nch Abstract
ette invention se rapporte a de nouvelles proteines secretees humaines
t a des acides nucleiques isoles contenant les regions de codage des
enes codant ces proteines. Cette invention se rapporte egalement a des
ecteurs, des cellules hotes, des anticorps et des procedes de
ecombinaison permettant de produire des proteines secretees humaines;
insi qu'a des procedes diagnostiques et therapeutiques servant a
iagnostiquer et a traiter des maladies, des troubles et/ou des etats
ies a ces nouvelles proteines secretees humaines.

/3,AB/28 (Item 8 from file: 349)
ALOG(R)File 349:PCT FULLTEXT

761296
TIVATION OF DENDRITIC CELLS TO ENHANCE IMMUNITY
TIVATION DE CELLULES DENDRITIQUES POUR ACCROITRE L'IMMUNITE
tent Applicant/Assignee:
CORNELL RESEARCH FOUNDATION INC, Cornell Business & Technology Park, 20
Thornwood Drive, Suite 105, Ithaca, NY 14850, US, US (Residence), US
(Nationality)
ventor(s):
CRYSTAL Ronald G, 1300 York Avenue, Box 96, New York, NY 10021, US,
KIKUCHI Toshiaki, 1300 York Avenue, Box F 401, New York, NY 10021, US,
FUSHIMI Toshiaki, 1300 York Avenue, Box F 401, New York, NY 10021, US,
gal Representative:
LARCHER Carol (et al) (agent), Leydig, Voit & Mayer, Ltd., Suite 4900,
Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780, US,
atent and Priority Information (Country, Number, Date):
Patent: WO 200073432 A2-A3 20001207 (WO 0073432)
Application: WO 2000US15308 20000601 (PCT/WO US0015308)
Priority Application: US 99137042 19990601
esignated States: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
ublication Language: English
iling Language: English
ulltext Word Count: 20171

sh Abstract
e present invention provides a method of enhancing immunity in a
mmal. The method comprises modifying a dendritic cell (DC)in vivo or ex
vo to produce a dendritic cell-mediator in the mammal. The dendritic
ll-mediator up-regulates DC in the mammal, thereby enhancing immunity
the mammal. The present invention further provides a method of
ducing an immune response to an antigen, cancer, or infectious disease
a mammal. In one embodiment, the method comprises administering the
tigen or an antigen of the cancer or infectious disease to a mammal,
ich has been treated as described above, whereupon an immune response
the antigen, cancer, or infectious disease, respectively, is induced
the mammal. In another embodiment, the method comprises administering
DC to a mammal as described above, however, the method further
mprises contacting the DC, which has been modified to produce a
ndritic cell-mediator, with the antigen or an antigen of the cancer or
fectious disease prior to administration of the DC to the mammal,
ereupon an immune response to the antigen, cancer or infectious
sease, respectively, is induced in the mammal.

nch Abstract
a presente invention concerne un procede permettant d'accroitre
'immunite chez un mammifere. Ce procede consiste a modifier une cellule
endritique (CD) in vivo ou ex vivo, et ce afin de produire chez le
ammifere un mediateur des cellules dendritiques. Ce mediateur des
ellules dendritiques regule positivement les CD du mammifere, stimulant
insi son systeme immunitaire. L'invention concerne egalement un procede
ermettant d'induire chez un mammifere une reponse immunitaire a un
ntigene, au cancer ou a une maladie infectieuse. Dans un mode de
ealisation, le procede consiste a administrer l'antigene ou un antigene
u cancer ou de la maladie infectieuse a un mammifere ayant ete traite
omme decrit ci-dessus, ce qui a pour effet d'induire une reponse
mmunitaire respectivement a l'antigene, au cancer ou a la maladie
nfectieuse. Dans un autre mode de realisation, le procede consiste a
dministrer a un mammifere une CD d'apres la description ci-dessus.
outefois, le procede consiste egalement a mettre en contact la CD,
realablement modifiee pour produire un mediateur des cellules
endritiques, avec l'antigene ou un antigene du cancer ou de la maladie
infectieuse, avant d'administrer la CD au mammifere, ce qui induit une
reponse immunitaire respectivement a l'antigene, au cancer ou a la
maladie infectieuse.

/3,AB/29 (Item 9 from file: 349)
ALOG(R)File 349:PCT FULLTEXT

570499
THOD OF AND COMPOSITIONS FOR IMMUNIZATION WITH THE i(%PSEUDOMONAS%) V
ANTIGEN
ROCEDE ET COMPOSITION POUR UNE IMMUNISATION AVEC L'ANTIGENE i(
%PSEUDOMONAS%) V
atent Applicant/Assignee:
MCW RESEARCH FOUNDATION INC,
nventor(s):
FRANK Dara W,
YAHR Timothy L,
SAWA Teiji,
WIENER-KRONISH Jeanine,
atent and Priority Information (Country, Number, Date):
Patent: WO 200033872 A2 20000615 (WO 0033872)
Application: WO 99US27796 19991123 (PCT/WO US9927796)
Priority Application: US 98109952 19981125; US 99126794 19990330
esignated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM
EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG UZ VN YU ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN GW ML MR NE SN TD TG
ublication Language: English

ltext Word Count: 7504

lish Abstract
method of inhibiting, moderating or diagnosing i(Psuedomonas eruginosa) infection is disclosed. In one embodiment, this method omprises inoculating a patient with an effective amount of %PcrV% ntigen.

nch Abstract
'invention concerne un procede destine a bloquer, ralentir ou iagnostiquer une infection par i(%Pseudomonas% aerungiosa). Dans un des odes operatoires, on injecte au patient une dose efficace d'antigene PcrV%.

3,AB/30 (Item 10 from file: 349)
LOG(R)File 349:PCT FULLTEXT

07974
EROMONE COMPOSITIONS AND METHODS OF USE IN CONTROLLING FUNGAL DISEASES IN PLANTS
MPOSITIONS PHEROMONALES ET LEURS PROCEDES D'UTILISATION POUR LA LUTTE CONTRE LES MALADIES FONGIQUES DANS LES PLANTES
tent Applicant/Assignee:
THE TEXAS A & M UNIVERSITY SYSTEM,
VAN ALFEN Neal J,
EBBOLE Daniel J,
BECKERMAN Janna L,
ZHANG Lei,
MCCABE Patricia,
KAZMIERCZAK Pam,
ventor(s):
VAN ALFEN Neal J,
EBBOLE Daniel J,
BECKERMAN Janna L,
ZHANG Lei,
MCCABE Patricia,
KAZMIERCZAK Pam,
tent and Priority Information (Country, Number, Date):
Patent: WO 9748719 A1 19971224
Application: WO 97US10364 19970617 (PCT/WO US9710364)
Priority Application: US 9619598 19960617
signated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
blication Language: English
lltext Word Count: 44290

glish Abstract
Disclosed are pheromone compositions comprising fungal mating factors, methods for making and using native and recombinant pheromone compositions and derivatives thereof in interfering with fungal pathogenesis, and methods for making and using these compositions for preventing fungal infection and disease in plants.

ench Abstract
L'invention concerne des compositions de pheromonales comprenant des facteurs d'appariement fongique, des procedes de fabrication et d'utilisation de compositions pheromonales natives et recombinees et leurs derives pour empecher la pathogenese fongique et des procedes de fabrication et d'utilisation de ces compositions pour prevenir l'infection fongique et les maladies dans les plantes.

Items	Description
2033	PCRV
223	S1 AND PSEUDOMONAS
175	S2 AND PROTEIN
2287108	S3 AND ANTIBODY OR ANTIBODIES
122	S4 AND S3
61	RD (unique items)

s6/3,ab/31-61
No matching display code(s) found in file(s): 107, 129, 135, 180, 225, 398, 441, 608, 624, 635, 761, 764, 810, 813

3,AB/31 (Item 11 from file: 349)
LOG(R)File 349:PCT FULLTEXT

86558
ORIN BINDING %PROTEIN% COMPOSITIONS AND METHODS OF USE
POSITIONS DE PROTEINES DE LIAISON DE LA DECORINE ET MODES D'UTILISATION

---

ent Applicant/Assignee:
HE TEXAS A & M UNIVERSITY SYSTEM,
EDIMMUNE INCORPORATED,
UO Betty P,
ooK Magnus,
ANSON Mark,
entor(s):
UO Betty P,
ooK Magnus,
ANSON Mark,
ent and Priority Information (Country, Number, Date):
Patent: WO 9727301 A1 19970731
Application: WO 96US17081 19961022 (PCT/WO US9617081)
Priority Application: US 96589711 19960122; WO 96US5886 19960424
signated States: AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
olication Language: English
lltext Word Count: 66294

glish Abstract
Disclosed are the dbp gene and dbp-derived nucleic acid segments from Borrelia burgdorferi, the etiological agent of Lyme disease, and DNA segments encoding dbp from related borrelias. Also disclosed are decorin binding %protein% compositions and methods of use. The DBP %protein% and antigenic epitopes derived therefrom are contemplated for use in the treatment of pathological Borrelia infections, and in particular, for use in the prevention of bacterial adhesion to decorin. DNA segments encoding these proteins and anti-(decorin binding %protein%) %antibodies% will also be of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of Borrelia colonization in an animal. These DNA segments and the peptides derived therefrom are contemplated for use in the preparation of vaccines and, also, for use as carrier proteins in vaccine formulations, and in the formulation of compositions for use in the prevention of Lyme disease.

rench Abstract
L'invention concerne le gene dbp et des segments d'acide nucleique derives de la dbp provenant de Borrelia burgdorferi, agent etiologique de la maladie de Lyme, ainsi que des segments d'ADN codant pour la dbp provenant de borrelias voisines. Elle concerne egalement des compositions de proteines de liaison de la decorine et leurs modes d'utilisation. Il est propose d'utiliser la proteine DBP, ainsi que les epitopes antigeniques qui en sont derives, pour le traitement des infections pathologiques a Borrelia et notamment pour la prevention de l'adhesion bacterienne a la decorine. Les segments d'ADN codant pour ces proteines et les anticorps anti-(proteine de liaison de la decorine) peuvent egalement etre utilises pour diverses applications de criblage, de

entor: Frank, Dara W., West Allis,
Yahr, Timothy L., Hanover, NH
Sawa, Teiji, San Francisco, CA
Wiener-Kronish, Jeanine, San Francisco, CA
ignee: MCW Research Foundation (02), Milwaukee, WI
The Regents of the University of California (02), Oakland, CA
California, University of Regents
Mcw Research Foundation Inc (Code: 13234 18617)
miner: Graser, Jennifer E. (Art Unit: 165)
Firm: Quarles & Brady LLP

	Publication Number	Kind	Date	Application Number	Filing Date
n Patent	US 6309651	A	20011030	US 99448339	19991123

ltext Word Count: 6880

tract:
A method of inhibiting, moderating or diagnosing %Pseudomonas% eruginosa infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of %PcrV% ntigen.

/3,AB/42 (Item 1 from file: 613)
ALOG(R)File 613:PR Newswire
2003 PR Newswire Association Inc. All rts. reserv.

589862 20011213SFTH026
terMune Announces Five Abstracts to Be Presented
Newswire
ursday, December 13, 2001 06:01 EST
URNAL CODE: PR LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT
CUMENT TYPE: NEWSWIRE
RD COUNT: 934

/3,AB/43 (Item 1 from file: 156)
ALOG(R)File 156:ToxFile
) format only 2003 The Dialog Corporation. All rts. reserv.

904037 NLM Doc No: CRISP/2000/HL59239-03 Sec. Source ID:
ISP/2000/HL59239-03
THE HOST RESPONSE TO CYTOTOXIC PROTEINS
WIENER-KRONISH JP
UNIV. OF CALIFORNIA, SAN FRANC, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, LIFORNIA 941
Source: Crisp Data Base National Institutes of Health
City or State: CALIFORNIA Zip Code: 941
Pub. Year: 2000
Sponsoring Agency: U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH RVICE; NATIONAL INSTITUTES OF HEALTH, NATIONAL HEART, LUNG, AND BLOOD STITUTE
Award Type: Grant
Document type: Research
Languages: ENGLISH
Record type: Completed
High mortality rates are associated with nosocomial lung infections due P.aeruginosa. As current antibiotic therapies are associated with a 0-80 percent mortality in this infection, improved methods for prevention nd therapy clearly are needed. The airspace instillation of PA103, a ytotoxic strain of P.aeruginosa, recreates the lung injury and sepsis seen n many of the patients with nosocomial pneumonia; the instillation of the acteria causes lung epithelial injury, bacteremia, organ failure and death f experimental animals. Over the last 4 years, our two laboratories have ollaborated on bacterial genetic experiments and animal physiology xperiments that have led to the discovery of novel P.aeruginosa

e III secretory system. Our previou[redacted]nvestigations have documented [redacted]t lung injury and dissemination of the airspace PA103 to the circulation related with the production of exoenzyme S by the bacteria. Two of the el extracellular products produced and secreted with exoenzyme S are U, a novel cytotoxin, and %PcrV%, a homolog of the Yersinia pestis V igen, which may affect host cytokine production. Our hypothesis is that se two bacterial products are the major virulence products of eruginosa and therapies directed against these products would prevent local and systemic injury due to the dissemination seen with this ection. To prove this hypothesis, we will compare the effects of these ly discovered bacterial products to P.aeruginosa endotoxin in terms of ir individual and combined effects on lung injury, lung inflammation and systemic inflammatory response. We will utilize isogenic transposon 03 strains that are selectively missing the genes for ExoU, for %PcrV% both of these genes. These 2 recombinant proteins are also available for eriments and we have obtained specific endotoxin antagonists and letically deficient mice for lipopolysaccharide binding %protein% to ermine the effects of these products in animals resistant to the effects endotoxin. We will determine whether these two bacterial products are ponsible for IL-10 production in vivo and if blockade of the IL-10 proves local host defense.

3,AB/50 (Item 3 from file: 266)
ALOG(R)File 266:FEDRIP
mp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

297072
IDENTIFYING NO.: 5R01AI44101-04 AGENCY CODE: CRISP
BIOLOGY OF %PCRV%
PRINCIPAL INVESTIGATOR: WIENER-KRONISH, JEANINE P.
ADDRESS: WIENERKJ@ANESTHESIA.UCSF.EDU UNIV OF CALIFORNIA,SAN FRANCISCO
3 PARNASSUS AVE RM S255 SAN FRANCISCO, CA 94143-0542
PERFORMING ORG.: UNIVERSITY OF CALIFORNIA SAN FRANCISCO, SAN FRANCISCO, LIFORNIA
SPONSORING ORG.: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
DATES: 2005/01/00 TO 2004/30/05 FY : 2003
SUMMARY: Nosocomial pneumonia is the second most common nosocomial fection and the leading cause of death from infection acquired in the spital. P. aeruginosa is the most frequent gram negative bacteria volved in nosocomial pneumonia, and nosocomial pneumonias associated with aeruginosa infections have up to a 60% mortality despite appropriate tibiotic treatment. Also patients who are chronically infected with P. ruginosa (i.e.: cystic fibrosis, HIV patients and bronchiectasis tients) become resistant to antibiotics and may die from their4 fections. Thus, there is an urgent need for novel treatments of P. ruginosa infections. The long-term objectives of this grant are to termine the cell biology of a Pseudomonal %protein%, %PcrV%. %PcrV% is rt of the bacterial type III secretory system; %PcrV% is involved in the anslocation of bacterial toxins by P.aeruginosa into eukaryotic cells. It also highly homologous to LcrV, a Yersinia %protein% also involved in e translocation. of that bacteria's toxins into eukaryotic cells. ntibodies% to LcrV can protect animals from infections caused by Y. stis and other Yersinia strains. Yet, although there are similarities tween LcrV and %PcrV%, there are also important differences in the roles LcrV compared to %PcrV% in the regulation of toxin secretion in the two rains. Therefore, %PcrV% warrants independent investigation. This group s shown that %PcrV% is accessible to %antibody% neutralization, that ntibody% attachment to %PcrV% blocks the translocation of the Pseudomonal xins into eukaryotic cells and that %antibody% to %PcrV% protects animals fected with virulent P. aeruginosa from lung injury, sepsis and death. herefore, therapies targeting %PcrV% appears clinically useful. Finally, ny virulent gram negative bacteria utilize the type III secretory system ich delivers bacterial toxins into eukaryotic cells. These gram negative cteria, including enteropathic E. coli, Yersinia, Salmonella, produce cterial proteins and structures similar to those found in P.aeruginosa. herefore, understanding the mechanism of %PcrV% 's role in bacterial anslocation into eukaryotic cells may help in the development of other herapies targeting this widespread gram negative bacterial secretory

stem.

/3,AB/51 (Item 1 from file: 445)
ALOG(R)File 445:IMS R&D Focus
2003 IMS Health & Affiliates. All rts. reserv.

015615
ug Name: MAb, %Pseudomonas% aeruginosa, InterMune
) Focus - August 27, 2001 (20010827)

MPANY INFORMATION:
Originator: InterMune; (USA); NA; NA; NA
Licensee/Licensor: %Protein% Design; (USA); NA; other; NA
Patent Assignee: %Protein% Design

UG INFORMATION:
Pharmacological Action: biotechnology; monoclonal %antibody%
Therapeutic Class Code: J7A9 (Other Unspecified Vaccines)
Clinical Indications: bacterial infection
Molecular Code: 7116950000

RRENT DEVELOPMENT STATUS:
Highest Phase: Preclinical (20)

/3,AB/52 (Item 1 from file: 19)
ALOG(R)File 19:Chem.Industry Notes
) 2003 Amer.Chem.Soc. All rts. reserv.

44330
Deals
urnal: BioCentury 9 (37, Pt. 2) p. B4 Date: 20010820
SN: 1097-7201 CODEN: BICEFS
Intermune Inc. (ITMN; Brisbane, CA) accepted from Protein Design Labs
c. (PDLI; Fremont, CA) a humanized version of ITMN's monoclonal antibody
ainst the PcrV surface protein of Pseudomonas aeruginosa under the
mpanies December 2000 deal.

/3,AB/53 (Item 1 from file: 42)
ALOG(R)File 42:Pharmaceuticl News Idx
)2003 ProQuest Info&Learning. All rts. reserv.

704926 83507263
Pseudomonas% targeted by %antibody%
UTHOR: Anonymous
plied Genetics News, v22, n2, p10
eptember 1, 2001
DDEN: AGNEEN DOCUMENT TYPE: Periodical; News JOURNAL CODE: AGN
ANGUAGE: English RECORD TYPE: Citation

5/3,AB/54 (Item 1 from file: 107)
IALOG(R)File 107:Adis R&D Insight
c) 2003 Adis Data Information BV. All rts. reserv.

0195426 000527
RUG NAME: %Pseudomonas% vaccine
ECORD REVISION DATE: 20030410
HO ATC CODE: J07A-X - Other bacterial vaccines
PHMRA ATC CODE: J7A9 - Other specified single component
ECHANISM OF ACTION: Immunostimulants; Immunomodulators

RIGINATOR COMPANY: Russian Academy of Medical Sciences (Russia); Nonindustrial source (Unknown); Louisiana State University (USA)
ARENT COMPANY: Louisiana State University; Nonindustrial source; Russian Academy of Medical Sciences

HEST PHASE: Preclinical

ELOPMENT STATUS: Preclinical, USA, Pseudomonal infections
No Development Reported, Russia, Pseudomonal infections

TEXT

roduction:
eudomonas% aeruginosa is a major cause of morbidity and mortality in
ients with cystic fibrosis. Organ transplant recipients are also at high
k of acquiring this infection.
e Academy of Medical Sciences in Moscow, Russia, was conducting phase I
dies with a P. aeruginosa vaccine containing cell-wall %protein%
tigens, but there have been no recent reports of ongoing development.
searchers at the Louisiana State University, USA, are conducting
eclinical studies with experimental vaccines containing P. aeruginosa
ter-membrane %protein% F.
searchers in the US appear to be developing a vaccine for %Pseudomonas%
ruginosa based on the P. aeruginosa homologue of the Yersinia V antigen.
e vaccine protected mice from subsequent challenge with P. aeruginosa in
eclinical studies/1/.

MMERCIAL SUMMARY:
Pseudomonal infections / Immunostimulant

Company	Region	Launch Date	Peak Sales	Patent Expiry
Shire	Wrld	2007	$300m	

ARMACOLOGY OVERVIEW:
Pharmacodynamics:
%Protein% F and synthetic peptide epitopes from %protein% F of
%Pseudomonas% aeruginosa protect mice from pseudomonal pneumonia
Immunogenicity:
Induces specific %antibodies% in volunteers
Mechanism of action:
Immunostimulants
Immunomodulators

INICAL OVERVIEW:
Route(s) of Administration: Injection, Parenteral
Drug Interactions:
Unknown.

/3,AB/55 (Item 2 from file: 107)
ALOG(R)File 107:Adis R&D Insight
) 2003 Adis Data Information BV. All rts. reserv.

175254 013254
UG NAME: Anti-%PcrV% %antibodies% - InterMune
CORD REVISION DATE: 20011120
NONYMS: Anti-%PcrV% immunoglobulin G; Anti-%PcrV% monoclonal %antibody%; Anti-%PcrV% polyclonal %antibody%; %Pseudomonas% infections research programme - InterMune; Research programme: pseudomonal infections - InterMune
O ATC CODE: J01X-X - Other antibacterials
HMRA ATC CODE: J8X - All Other Anti-Infectives
ECHANISM OF ACTION: %PcrV% inhibitors; %Protein% inhibitors

RIGINATOR COMPANY: InterMune (USA); Medical College of Wisconsin (USA); University of California at San Francisco (USA)
ARENT COMPANY: California State University; InterMune; Medical College of Wisconsin
THER COMPANY: %Protein% Design Labs

GHEST PHASE: Preclinical

VELOPMENT STATUS: Preclinical, USA, Pseudomonal infections

TEXT

troduction:
terMune Inc. (USA) is involved in the development of anti-%PcrV%
ntibodies% for the potential treatment of pseudomonal infections. %PcrV%
a %protein% of the type III secretory system of %Pseudomonas% aeruginosa
at facilitates the virulence of these bacteria.
monoclonal form of the anti-%PcrV% %antibody% has been developed by the
dical College of Wisconsin, Milwaukee (Wisconsin, USA) and the University
California, San Francisco (USA). In August 2001, it was announced that,
per its agreement with InterMune, %Protein% Design Labs Inc. had
ccessfully humanised the anti-%PcrV% monoclonal %antibody%. Under the
rms of the agreement with InterMune, %Protein% Design Labs will be
titled to annual maintenance payments and royalties on any product sales.
terMune is now working towards moving the %antibody% to the clinic by the
d of 2002. The %antibody% is reportedly effective in animal models of
fection.
preclinical study conducted by the University of California at San
ancisco and funded by InterMune have indicated that treatment with a
lyclonal form of anti-%PcrV% %antibody% may have potential for the
provement of lung damage and the prevention of septic shock/1/.
ARMACOLOGY OVERVIEW:
Pharmacodynamics:
Mechanism of action:
%PcrV% inhibitors
%Protein% inhibitors

INICAL OVERVIEW:
Drug Interactions:
Unknown.

/3,AB/56 (Item 1 from file: 129)
ALOG(R)File 129:PHIND(Archival)
) 2003 PJB Publications, Ltd. All rts. reserv.

722774
terMune to develop %Pseudomonas% treatment:
Scrip 2672 p15, August 24, 2001 (20010824)
STORY TYPE: B WORD COUNT: 95

/3,AB/57 (Item 2 from file: 129)
ALOG(R)File 129:PHIND(Archival)
) 2003 PJB Publications, Ltd. All rts. reserv.

690762
terMune/%Protein% Design Labs to collaborate on monoclonal %antibody%:
Scrip 2602 p10, December 20, 2000 (20001220)
STORY TYPE: B WORD COUNT: 105

/3,AB/58 (Item 1 from file: 761)
ALOG(R)File 761:Datamonitor Market Res.
) 2003 Datamonitor. All rts. reserv.

141624

WS HEADLINES HEPATITIS AND OTHER VIRAL INFECTIONS: 7.0 NEWS HEADLINES:
OTHER VIRAL INFECTIONS (CONT.)

in Title: THERAPEUTIC REVIEW VIRAL INFECTIONS
ub. Date: October 08, 2001
Source: DATAMONITOR
elephone: +44 20 7675 7000

rd Count: 991 (1 pp.)
Language: English

Country: WORLD
Industry: HEALTH CARE
mpany Names (DIALOG Generated): American Medical Association ; Department of Medicine ; Disease Control ; Dynavax Technologies ; Genesto A/S ; Health Canada ; Immunology ; InterMune Inc ; Journal ; Medarex Inc ; Medical College of Wisconsin ; National Center for Infectious Diseases ; New England Journal ; New York Hospital Medical Center of Queens ; NIAID ; Oxford Health Plans ; Pittsburgh Graduate School ; Prevention ; %Protein% Design Labs Inc ; Public Health ; National Institute of Allergy and Infectious Diseases ; National Institute of Allergy and Infectious Diseases ; Therapeutic Products ; University of California San Francisco ; University of Pittsburgh Graduate School of Public Health ; University of Washington School of Medicine ; Washington School

---

/3,AB/59 (Item 2 from file: 761)
ALOG(R)File 761:Datamonitor Market Res.
) 2003 Datamonitor. All rts. reserv.

141577

CTERIAL INFECTIONS-UPDATE: 1.0 R&D UPDATE

in Title: THERAPEUTIC REVIEW
ub. Date: October 08, 2001
Source: DATAMONITOR
elephone: +44 20 7675 7000
rd Count: 1420 (1 pp.)
Language: English

Country: WORLD
Industry: HEALTH CARE
mpany Names (DIALOG Generated): Abbott Laboratories ; Antex Biologics Inc ; AntiCancer Inc ; Cystic Fibrosis Foundation Therapeutics Inc ; CDI ; Demegen Inc ; Duke University Medical Center ; Infectech Inc ; InterMune Inc ; Journal ; Medical College of Wisconsin ; Molecular Genetics ; National Academy ; New York Hospital Medical Center of Queens ; %Protein% Design Labs Inc ; State Serum Institute ; Rockefeller University ; University of California San Francisco

/3,AB/60 (Item 1 from file: 764)
ALOG(R)File 764:BCC Market Research
) 2003 Business Communication Co. All rts. reserv.

182169

MMERCIAL BIOTECHNOLOGY INDUSTRY REVIEW: %ANTIBODIES%: %ANTIBODY% DRUG FOR %PSEUDOMONAS% INFECTION

in Title: COMMERCIAL BIOTECHNOLOGY INDUSTRY REVIEW
ub. Date: APRIL 2002
Source: BUSINESS COMMUNICATIONS COMPANY, INCORPORATED
elephone: (203) 853-4266
rd Count: 408 (1 pp.)
Language: English

Country: UNITED STATES
Industry: BIOTECHNOLOGY, HEALTH CARE
mpany Names (DIALOG Generated): InterMune Inc ; Journal ; Medical College of Wisconsin ; %Protein% Design Labs Inc ; University of California

4911 Supplier Number: 54353697
archers Find Way To Immunize Against Fatal Bacterium.
rculosis & Airborne Disease Weekly, pNA
l 12, 1999
uage: English Record Type: Fulltext
ment Type: Newsletter; Trade
Count: 712

,AB/18 (Item 1 from file: 20)
OG(R)File 20:Dialog Global Reporter

01323
cine developed to fight deadly lung infections in critically ill
MICAL BUSINESS NEWSBASE (BIOTECHNOLOGY NEWSWATCH) , p5
il 26, 1999
RNAL CODE: FBNW LANGUAGE: English RECORD TYPE: FULLTEXT
D COUNT: 101

Researchers from the Medical College of Wisconsin and the University California San Francisco have reported in the journal Nature Medicine t by using an %antibody% against the %PcrV% %protein%, they were able to p the bacterium %Pseudomonas% aeruginosa (responsible for serious and reatable lung infections in cystic fibrosis and critically ill patients) m injecting its toxins.
This research was carried out on mice.

3,AB/19 (Item 1 from file: 440)
LOG(R)File 440:Current Contents Search(R)

242459 References: 34
TLE: Therapeutic administration of anti-%PcrV% F(ab ')(2) in sepsis associated with %Pseudomonas% aeruginosa
THOR(S): Shime N; Sawa T; Fujimoto J; Faure K; Allmond LR; Karaca T; Swanson BL; Spack EG; Wiener-Kronish JP (REPRINT)
THOR(S) E-MAIL: wienerkj@anesthesia.ucsf.edu
RPORATE SOURCE: Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, Box 0542/San Francisco//CA/94143 (REPRINT); Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, /San Francisco//CA/94143; Univ Calif San Francisco, Dept Med, /San Francisco//CA/94143; Kyoto Prefectural Univ Med, Dept Anesthesiol & Intens Care, /Kyoto//Japan/; InterMune Inc, /Brisbane//CA/94005
BLICATION TYPE: JOURNAL
BLICATION: JOURNAL OF IMMUNOLOGY, 2001, V167, N10 (NOV 15), P5880-5886
NUINE ARTICLE#: 491JZ
BLISHER: AMER ASSOC IMMUNOLOGISTS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN: 0022-1767
ANGUAGE: English DOCUMENT TYPE: ARTICLE
BSTRACT: The effects of rabbit-derived polyclonal Ab against %PcrV%, a protein% involved in the translocation of type III secreted toxins of Pseudomonas% aeruginosa, was investigated in two animal models of P. eruginosa sepsis. In a mouse survival study, the i.v. administration of nti-%PcrV% IgG after the airspace instillation of a lethal dose of A eruginosa resulted ill the complete survival of the animals. In a rabbit odel of septic shock associated with %Pseudomonas%-induced lung injury, nimals treated with anti-%PcrV% IgG intratracheally or Lv. had significant ecreases in lung injury, bacteremia, and plasma TNF-alpha and significant mprovement in the hemodynamic parameters associated with shock compared ith animals treated in a similar manner with nonspecific control IgG. The dministration of anti-%PcrV% F(ab')(2) showed protective effects omparable to those of whole anti-%PcrV% IgG. These results document that he therapeutic administration of anti-%PcrV% IgG blocks the type III

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Delivery of Yop effector proteins by pathogenic Yersinia across the karyotic cell membrane requires LcrV, YopB and YopD. These proteins were so required for channel formation in infected erythrocytes and, using fferent osmolytes, the contact-dependent haemolysis assay was used to udy channel size. Channels associated with LcrV were around 3 nm, whereas e homologous %PcrV% %protein% of %Pseudomonas% aeruginosa induced annels of around 2 nm in diameter. In lipid bilayer membranes, purified rV and %PcrV% induced a stepwise conductance increase of 3 nS and 1 nS, spectively, in 1 M KCl. The regions important for channel size were calized to amino acids 127-195 of LcrV and to amino acids 106-173 of crV% . The size of the channel correlated with the ability to translocate p effectors into host cells. We suggest that LcrV is a size-determining ructural component of the Yop translocon.

/3,AB/40 (Item 1 from file: 73)
ALOG(R)File 73:EMBASE
) 2003 Elsevier Science B.V. All rts. reserv.

390411 EMBASE No: 2001404624
Therapeutic administration of anti-%PcrV% F(abprime)SUB2 in sepsis sociated with %Pseudomonas% aeruginosa
Shime N.; Sawa T.; Fujimoto J.; Faure K.; Allmond L.R.; Karaca T.; anson B.L.; Spack E.G.; Wiener-Kronish J.P.
Dr. J.P. Wiener-Kronish, Box 0542, Department of Anesthesia, University of California, San Francisco, CA 94143-0542 United States
AUTHOR EMAIL: wienerkj@anesthesia.ucsf.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 NOV 2001, 167/10 (5880-5886)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 34

The effects of rabbit-derived polyclonal Ab against %PcrV%, a %protein% volved in the translocation of type III secreted toxins of %Pseudomonas% ruginosa, was investigated in two animal models of P. aeruginosa sepsis. a mouse survival study, the i.v. administration of anti-%PcrV% IgG after e airspace instillation of a lethal dose of P. aeruginosa resulted in the mplete survival of the animals. In a rabbit model of septic shock sociated with %Pseudomonas%-induced lung injury, animals treated with ti-%PcrV% IgG intratracheally or i.v. had significant decreases in lung jury, bacteremia, and plasma TNF-alpha and significant improvement in the modynamic parameters associated with shock compared with animals treated a similar manner with nonspecific control IgG. The administration of ti-%PcrV% F(abprime)SUB2 showed protective effects comparable to those of ole anti-%PcrV% IgG. These results document that the therapeutic ministration of anti-%PcrV% IgG blocks the type III secretion stem-mediated virulence of P. aeruginosa and prevents septic shock and ath, and that these protective effects are largely Fc independent. We nclude that Ab therapy neutralizing the type III secretion system has gnificant potential against lethal P. aeruginosa infections.

/3,AB/41 (Item 1 from file: 654)
ALOG(R)File 654:US PAT.FULL.
) FORMAT ONLY 2003 THE DIALOG CORP. All rts. reserv.

92884
rwent Accession: 2000-431202
ility
Method of and compositions for immunization with the %pseudomonas% V tigen
%A METHOD O%F INHIBITING, MODERATING OR DIAGNOSING %PSEUDOMONAS% RUGINOSA INFECTION IS DISCLOSED.

tracellular products which are synthesized and secreted and coordinately ntrolled with exoenzyme S by a type III secretory system. Our previous vestigations have documented that the lung injury and dissemination of e airspace PA103 to the circulation correlated with the production of oenzyme S by the bacteria. Two of the novel extracellular products oduced and secreted with exoenzyme S are ExoU, a novel cytotoxin, and crV% , a homolog of the Yersinia pestis V antigen, which may affect host tokine production. Our hypothesis is that these two bacterial products e the major virulence products of P.aeruginosa and therapies directed ainst these products would prevent the local and systemic injury due to e dissemination seen with this infection. To prove this hypothesis, we ll compare the effects of these newly discovered bacterial products to aeruginosa endotoxin in terms of their individual and combined effects on ng injury, lung inflammation and the systemic inflammatory response. We ll utilize isogenic transposon PA103 strains that are selectively missing e genes for ExoU, for %PcrV% or both of these genes. These 2 recombinant oteins are also available for experiments and we have obtained specific dotoxin antagonists and genetically deficient mice for lipopolysaccharide nding %protein% to determine the effects of these products in animals sistant to the effects of endotoxin. We will determine whether these two cterial products are responsible for IL-10 production in vivo and if ockade of the IL-10 improves local host defense.

/3,AB/44 (Item 2 from file: 156)
ALOG(R)File 156:ToxFile
) format only 2003 The Dialog Corporation. All rts. reserv.

900390 NLM Doc No: CRISP/2000/AI44101-01A2 Sec. Source ID: ISP/2000/AI44101-01A2
BIOLOGY OF %PCRV%
WIENER-KRONISH JP
UNIV OF CALIFORNIA, SAN FRAN, 374 PARNASSUS AVE, SAN FRANCISCO, CA 143-0648
Source: Crisp Data Base National Institutes of Health
City or State: CALIFORNIA Zip Code: 94143-0648
Pub. Year: 2000
Sponsoring Agency: U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH RVICE; NATIONAL INSTITUTES OF HEALTH, NATIONAL INSTITUTE OF ALLERGY AND FECTIOUS DISEASES
Award Type: Grant
Document type: Research
Languages: ENGLISH
Record type: Completed
Nosocomial pneumonia is the second most common nosocomial infection and e leading cause of death from infection acquired in the hospital. P. ruginosa is the most frequent gram negative bacteria involved in socomial pneumonia, and nosocomial pneumonias associated with P. ruginosa infections have up to a 60% mortality despite appropriate tibiotic treatment. Also patients who are chronically infected with P. ruginosa (i.e.: cystic fibrosis, HIV patients and bronchiectasis tients) become resistant to antibiotics and may die from their4 fections. Thus, there is an urgent need for novel treatments of P. ruginosa infections. The long-term objectives of this grant are to termine the cell biology of a Pseudomonal %protein%, %PcrV%. %PcrV% is rt of the bacterial type III secretory system; %PcrV% is involved in the anslocation of bacterial toxins by P.aeruginosa into eukaryotic cells. It also highly homologous to LcrV, a Yersinia %protein% also involved in e translocation. of that bacteria's toxins into eukaryotic cells. ntibodies% to LcrV can protect animals from infections caused by Y. stis and other Yersinia strains. Yet, although there are similarities tween LcrV and %PcrV%, there are also important differences in the roles LcrV compared to %PcrV% in the regulation of toxin secretion in the two rains. Therefore, %PcrV% warrants independent investigation. This group s shown that %PcrV% is accessible to %antibody% neutralization, that ntibody% attachment to %PcrV% blocks the translocation of the Pseudomonal xins into eukaryotic cells and that %antibody% to %PcrV% protects animals fected with virulent P. aeruginosa from lung injury, sepsis and death. erefore, therapies targeting %PcrV% appears clinically useful. Finally,

ny virulent gram negative bacteria utilize the type III secretory system
ich delivers bacterial toxins into eukaryotic cells. These gram negative
cteria, including enteropathic E. coli, Yersinia, Salmonella, produce
cterial proteins and structures similar to those found in P.aeruginosa.
erefore, understanding the mechanism of %PcrV% 's role in bacterial
anslocation into eukaryotic cells may help in the development of other
erapies targeting this widespread gram negative bacterial secretory
stem.

/3,AB/45 (Item 1 from file: 135)
ALOG(R)File 135:NewsRx Weekly Reports
) 2003 NewsRx. All rts. reserv.

00052436 (USE FORMAT 7 OR 9 FOR FULLTEXT)
noclonal %Antibody% Developed For Treatment/Prevention Of Infection
otech Week, September 19-26, 2001, p.19

CUMENT TYPE: Expanded Reporting LANGUAGE: English
CORD TYPE: FULLTEXT
RD COUNT: 418

/3,AB/46 (Item 2 from file: 135)
ALOG(R)File 135:NewsRx Weekly Reports
) 2003 NewsRx. All rts. reserv.

00040190 (USE FORMAT 7 OR 9 FOR FULLTEXT)
ntibody% Humanization Agreement Announced
otech Week, December 20, 2000, p.22

CUMENT TYPE: Research News LANGUAGE: English
CORD TYPE: FULLTEXT
RD COUNT: 189

/3,AB/47 (Item 1 from file: 9)
ALOG(R)File 9:Business & Industry(R)
) 2003 Resp. DB Svcs. All rts. reserv.

57021 Supplier Number: 02457021
terMune Pharmaceutical, Inc. Researchers Find Way To Immunize Against
Fatal Bacterium
nterMune Pharmaceutical signs licensing agreement with university
researchers to develop an %antibody% therapy and vaccine against the
%Pseudomonas% aeruginosa bacterium)
niel J. DeNoon's Insider Newsfile, p N/A
ril 12, 1999
CUMENT TYPE: Newsletter (United States)
NGUAGE: English RECORD TYPE: Fulltext
RD COUNT: 713

STRACT:
terMune Pharmaceutical Inc has signed a licensing agreement with
searchers from the University of California (San Francisco) and the
dical College of Wisconsin to develop an %antibody% therapy and vaccine
ainst the %Pseudomonas% aeruginosa bacterium, which is responsible for
st hospital-acquired pneumonia deaths. This virulent class of microbes
s become very resistant to antibiotics. However, the research group
veloped an alternative to antibiotics to fight the microbes. Over $2
l/yr are spent to fight hospital pneumonia in the US. The researchers
ve developed an %antibody% against one of the proteins that delivers
tal toxins to host cells. The %antibody% has been shown to block
seudomonas% from delivering toxins into lung cells and has also shown its
ility to offer immunity against the %Pseudomonas% bacterium. The article
rther discusses the research collaboration.

/3,AB/48 (Item 1 from file: 266)

ALOG(R)File 266:FEDRIP
mp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

344625
IDENTIFYING NO.: 1R41HL67600-01A1 AGENCY CODE: CRISP
Animal Testing of a Blocking %Antibody% of %PcrV%
PRINCIPAL INVESTIGATOR: SAWA, TEIJI
ADDRESS: SAWAT@ANAESTHESIA.UCSF.EDU UNIVERSITY OF CALIFORNIA, SAN FR 513
RNASSUS AVE, RM S255 SAN FRANCISCO, CA 94143-0542
PERFORMING ORG.: INTERMUNE PHARMACEUTICALS, INC., BURLINGAME, CALIFORNIA
SPONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
DATES: 2001/01/02 TO 2006/30/03 FY : 2002
SUMMARY: DESCRIPTION (provided by applicant): This grant will determine
e efficacy of a humanized monoclonal %antibody% in treating a lethal
seudomonas% -induced lung injury. We have shown that the airspace
stillation of a strain of %Pseudomonas% aeruginosa that contains the type
system predictably causes lung necrosis, sepsis and death (J Clin Invest
99). We have also shown that the systemic administration of polyclonal
ntibody% raised against recombinant %PcrV%, a type III bacterial
rotein% involved in translocating the bacterial toxins into eukaryotic
lls, prevented lung injury and death in mice pretreated with the
ntibody% (Nature Med 1999). More recently, we have identified a mouse
ciPcrV monoclonal %antibody% that when administered prior to the
cterial instillation, prevented mortality in mice airspace-infected with
e virulent %Pseudomonas%. The proposed experiments will determine whether
e systemic or lung administration of a humanized monoclonal %antibody%
fter the airspace instillation of the virulent %Pseudomonas% improves
modynamics, gas exchange and/or improves the septicemia in
rspace-infected, anesthetized rabbits. These results will be critical for
ciding how to plan a clinical trial; the results will determine whether
e %antibody% should be utilized as a therapy or as a prophylactic
eatment. PROPOSED COMMERCIAL APPLICATIONS: %Pseudomonas% aeruginosa is a
jor cause of hospital infection, accounting for 20% of nosoconual
eumonias, 10-15% of nosocomial urinary tract infections, and 10% of
psis. In addition, P. aeruginosa infection is the major cause of
rtality in cystic fibrosis. Current treatment is associated with a high
te of antibiotic resistance and a 25-50% failure rate. The proposed
eatment provides a novel approach to the prevention of P. aeruginosa
fection in patients at high risk for this infection, including patients
ventilators, burn patients, patients with in-dwelling catheters,
utropenic patients, an patients with cystic fibrosis.

/3,AB/49 (Item 2 from file: 266)
ALOG(R)File 266:FEDRIP
mp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

42184
IDENTIFYING NO.: 5R01HL59239-04 AGENCY CODE: CRISP
HOST RESPONSE TO CYTOTOXIC PROTEINS
PRINCIPAL INVESTIGATOR: WIENER-KRONISH, JEANINE P
ADDRESS: JWK@JEMO.UCSF.EDU UNIV. OF CALIFORNIA, SAN FRANCIS UNIVERSITY OF
LIFORNIA SAN FRANCISCO, CALIFORNIA 94143
PERFORMING ORG.: UNIVERSITY OF CALIFORNIA SAN FRANCISCO, SAN FRANCISCO,
LIFORNIA
PONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
ATES: 2007/06/98 TO 2006/30/03 FY : 2001
UMMARY: High mortality rates are associated with nosocomial lung
ections due to P.aeruginosa. As current antibiotic therapies are
ociated with a 50-80 percent mortality in this infection, improved
hods for prevention and therapy clearly are needed. The airspace
tillation of PA103, a cytotoxic strain of P.aeruginosa, recreates the
g injury and sepsis seen in many of the patients with nosocomial
umonia; the instillation of the bacteria causes lung epithelial injury,
teremia, organ failure and death of experimental animals. Over the last
years, our two laboratories have collaborated on bacterial genetic
eriments and animal physiology experiments that have led to the
covery of novel P.aeruginosa extracellular products which are
thesized and secreted and coordinately controlled with exoenzyme S by a

cretion system-mediated virulence of P. aeruginosa and prevents septic
ock and death, and that these protective effects are largely Fc
dependent. We conclude that. Ab therapy neutralizing the type III
cretion system has significant potential against lethal P. aeruginosa
fections.

/3,AB/20 (Item 2 from file: 440)
ALOG(R)File 440:Current Contents Search(R)
) 2003 Inst for Sci Info. All rts. reserv.

359287 References: 29
TLE: Sera from adult patients with cystic fibrosis contain %antibodies%
to %Pseudomonas% aeruginosa type III apparatus
THOR(S): Moss J; Ehrmantraut ME; Banwart BD; Frank DW; Barbieri
JT (REPRINT)
THOR(S) E-MAIL: toxin@mcw.edu
RPORATE SOURCE: Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701
Watertown Plank Rd/Milwaukee//WI/53226 (REPRINT); Med Coll Wisconsin,
Dept Microbiol & Mol Genet, /Milwaukee//WI/53226; NHLBI, NIH,
/Bethesda//MD/20892; Med Coll Wisconsin, Dept Pediat,
/Milwaukee//WI/53226
UBLICATION TYPE: JOURNAL
UBLICATION: INFECTION AND IMMUNITY, 2001, V69, N2 (FEB), P1185-1188
ENUINE ARTICLE#: 394MW
UBLISHER: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904
USA
SSN: 0019-9567
ANGUAGE: English DOCUMENT TYPE: ARTICLE

BSTRACT: Expression of type III proteins of %Pseudomonas% aeruginosa in
atients with cystic fibrosis (CF) was investigated by measuring the immune
esponse against components of the type III pathway. Twenty-three of the 33
era contained %antibodies% against %PcrV%, a %protein% involved in
ranslocation of type III cytotoxins into eukaryotic cells, and 11 of 33
ad %antibodies% against ExoS, while most CF sera contained %antibodies%
gainst PopB and PopD, components of the type III apparatus. These data
ndicate that P. aeruginosa commonly expresses components of the type III
ranslocation apparatus in adult CF patients.

5/3,AB/21 (Item 1 from file: 349)
IALOG(R)File 349:PCT FULLTEXT
c) 2003 WIPO/Univentio. All rts. reserv.

0930432
ETHOD AND COMPOSITIONS FOR IMMUNIZATION WITH THE %PSEUDOMONAS% V ANTIGEN
ROCEDE ET COMPOSITIONS D'IMMUNISATION AVEC L'ANTIGENE V DE <I>
%PSEUDOMONAS%</I>
atent Applicant/Assignee:
MCW RESEARCH FOUNDATION INC, 8701 Watertown Plank Road, Milwaukee, WI
53226, US, US (Residence), US (Nationality), (For all designated states
except: US)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, 1111 Franklin Street, 12th
floor, Oakland, CA 94607, US, US (Residence), US (Nationality), (For
all designated states except: US)
atent Applicant/Inventor:
FRANK Dara W, 5425 West Hayes Avenue, West Allis, WI 53219, US, US
(Residence), US (Nationality), (Designated only for: US)
WIENER-KRONISH Jeannine, 1908 16th Avenue, San Francisco, CA 94116, US,
US (Residence), US (Nationality), (Designated only for: US)
YAHR Timothy L, 302 Olde Hickory Ridge, Coralville, IA 52241, US, US
(Residence), US (Nationality), (Designated only for: US)
SAWA Teiji, 1251 17th Avenue #6, San Francisco, CA 94122, US, US
(Residence), US (Nationality), (Designated only for: US)
FRITZ Robert B, 3205 South Vermont Avenue, Milwaukee, WI 53207, US, US
(Residence), US (Nationality), (Designated only for: US)
egal Representative:
BAKER Jean C (agent), Quarles & Brady LLP, 411 East Wisconsin Avenue,

diagnostic et de therapeutique, parmi lesquelles l'immunisation passive et active, ainsi que des methodes de prevention de la colonisation par Borrelia chez l'animal. Il est propose d'utiliser ces segments d'ADN et les peptides qui en sont derives pour la preparation de vaccins et comme proteines porteuses dans des formulations de vaccins, ainsi que dans la formulation de compositions destinees a la prevention de la maladie de Lyme.

/3,AB/32 (Item 1 from file: 399)
ALOG(R)File 399:CA SEARCH(R)
) 2003 American Chemical Society. All rts. reserv.

137323925 CA: 137(22)323925x JOURNAL
Generation and characterization of a protective monoclonal antibody to eudomonas aeruginosa PcrV
AUTHOR(S): Frank, Dara W.; Vallis, Amy; Wiener-Kronish, Jeanine P.; y-Burman, Arup; Spack, Edward G.; Mullaney, Brian P.; Megdoud, Mehdi; rks, James D.; Fritz, Robert; Sawa, Teiji
LOCATION: Department of Microbiology and Molecular Genetics, Medical llege of Wisconsin, Milwaukee, WI, USA
JOURNAL: J. Infect. Dis. (Journal of Infectious Diseases) DATE: 2002 VOLUME: 186 NUMBER: 1 PAGES: 64-73 CODEN: JIDIAQ ISSN: 0022-1899
LANGUAGE: English PUBLISHER: University of Chicago Press

/3,AB/33 (Item 2 from file: 399)
ALOG(R)File 399:CA SEARCH(R)
) 2003 American Chemical Society. All rts. reserv.

137184454 CA: 137(13)184454c PATENT
Pseudomonas aeruginosa V antigen and antibodies for diagnosis, prognosis d treatment of infection by Pseudomonas aeruginosa
INVENTOR(AUTHOR): Frank, Dara W.; Wiener-Kronish, Jeannine; Yahr, Timothy ; Sawa, Teiji; Fritz, Robert B.
LOCATION: USA
ASSIGNEE: Mcw Research Foundation, Inc.; The Regents of the University of lifornia
PATENT: PCT International ; WO 200264161 A2 DATE: 20020822
APPLICATION: WO 2002US2382 (20020125) *US 770916 (20010126) *US PV264795 0010129)
PAGES: 63 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/104A; 1K-048/00B; G01N-033/569B; C07K-016/12B; A61K-039/40B; A61P-031/04B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; ; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; ; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; ; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; ; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; ; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; ; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ; MR; NE; SN; TD; TG

/3,AB/34 (Item 3 from file: 399)
ALOG(R)File 399:CA SEARCH(R)
) 2003 American Chemical Society. All rts. reserv.

131057511 CA: 131(5)57511v JOURNAL
Active and passive immunization with the Pseudomonas V antigen protects ainst type III intoxication and lung injury
AUTHOR(S): Sawa, Teiji; Yahrs, Timothy L.; Ohara, Maria; Kurahashi, yoyasu; Gropper, Michael A.; Wiener-Kronish, Jeanine P.; Frank, Dara W.
LOCATION: Cardiovascular Research Institute, University of California, n Francisco, CA, 94143-0542, USA
JOURNAL: Nat. Med. (N. Y.) DATE: 1999 VOLUME: 5 NUMBER: 4 PAGES: 2-398 CODEN: NAMEFI ISSN: 1078-8956 LANGUAGE: English PUBLISHER: ure America

/3,AB/35 (Item 1 from file: 5)
ALOG(R)File 5:Biosis Previews(R)
) 2003 BIOSIS. All rts. reserv.

870701 BIOSIS NO.: 200200499522
velopment and characterization of monoclonal %antibody% to %Pseudomonas%
aeruginosa type III secreted %protein% %PcrV%.
THOR: Sawa T(a); Vallis A; Spack E G; Frank D W; Wiener-kronish J P(a)
THOR ADDRESS: (a)Univ. of CA, San Francisco, San Francisco, CA**USA
URNAL: Abstracts of the Interscience Conference on Antimicrobial Agents
d Chemotherapy 41p56 2001
DIUM: print
NFERENCE/MEETING: 41st Annual Meeting of the Interscience Conference on
timicrobial Agents and Chemotherapy Chicago, Illinois, USA September
-25, 2001
CORD TYPE: Abstract
NGUAGE: English

STRACT: Background: We reported that P. aeruginosa V-antigen (%PcrV%) is
a protective antigen against P. aeruginosa infection and rabbit
polyclonal %antibody% to %PcrV% can neutralize the virulence associated
with the type III secretion system (Nature Medicine, 5:392, 1999). We
developed a murine monoclonal %antibody% against %PcrV%. We examined the
effects of this %antibody% on lethal P. aeruginosa pneumonia in our mouse
model and compared it to rabbit anti-%PcrV% IgG. Method: Murine
monoclonal %antibodies% against %PcrV% were produced by hybridoma cells;
%antibody% blocking functions against type III secretion system were
tested in our mouse model of P. aeruginosa pneumonia. Purified monoclonal
%antibody% was mixed with a lethal dose (5X105 CFU/mouse) of cytotoxic P.
aeruginosa (PA103) and directly instilled into the lungs of mice.
Survival of mice was monitored for a week. The %antibody% was also tested
for its effects in passive immunization in infected mice. Results: The
clone m166 which showed higher affinity in preliminary screening and also
demonstrated potent protective effects on the survival of mice infected
with PA103. Eighty percent of mice survived after the instillation of a
lethal dose of PA103 with 10 micrograms of m166, while no mice survived
without receiving IgG. Passive immunization, 100 micrograms of m166
injected intraperitoneally 1 hour before the instillation of a lethal
dose of PA103 saved 90% of mice infected with PA103 while control mice
receiving saline instead of IgG all died in two days. Conclusion:
Specific murine monoclonal %antibody% against %PcrV% showed comparable
potency to a rabbit polyclonal anti-%PcrV% IgG in an animal model of P.
aeruginosa infection. The monoclonal %antibody% against %PcrV% has the
potential to be a therapeutic agent in P. aeruginosa infection.

91

3,AB/36 (Item 1 from file: 636)
LOG(R)File 636:Gale Group Newsletter DB(TM)
2003 The Gale Group. All rts. reserv.

57589 Supplier Number: 77275772
er News To Note.(Brief Article)
WORLD Today, v12, n160, pNA
ust 17, 2001
guage: English Record Type: Fulltext
icle Type: Brief Article
ument Type: Magazine/Journal; Trade
d Count: 1121

3,AB/37 (Item 1 from file: 155)
LOG(R)File 155:MEDLINE(R)
format only 2003 The Dialog Corp. All rts. reserv.

48119 21659906 PMID: 11801671
ersinia enterocolitica evasion of the host innate immune response by V

ıtigen-induced IL-10 production of macrophages is abrogated in
-10-deficient mice.
Sing Andreas; Roggenkamp Andreas; Geiger Anna M; Heesemann Jurgen
Max von Pettenkofer-Institut fur Hygiene und Medizinische Mikrobiologie,
ttenkoferstrasse 9a, 80336 Munich, Germany.
Journal of immunology (Baltimore, Md. - 1950) (United States) Feb 1
02, 168 (3) p1315-21, ISSN 0022-1767 Journal Code: 2985117R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
The virulence-associated V Ag (LcrV) of pathogenic Yersinia species is
rt of the translocation apparatus, required to deliver antihost effector
oteins (Yersinia outer proteins) into host cells. An orthologous
rotein% (denoted as %PcrV%) has also been identified in the ExoS regulon
%Pseudomonas% aeruginosa. Additionally, it is known that LcrV is
leased by yersiniae into the environment and that LcrV causes an
munosuppressive effect when injected into mice. In this study, we
monstrate for the first time that rLcrV, but not %PcrV%, is capable of
ppressing TNF-alpha production in zymosan A-stimulated mouse macrophages
d the human monocytic Mono-Mac-6 cell line. The underlying mechanism of
F-alpha suppression could be assigned to LcrV-mediated IL (IL)-10
oduction, because 1) LcrV induces IL-10 release in macrophages, 2)
ti-IL-10 Ab treatment completely abrogated TNF-alpha suppression, and 3)
F-alpha suppression was absent in LcrV-treated macrophages of
-10-deficient (IL-10-/-) mice. The relevance of LcrV-mediated
munosuppression for the pathogenicity of yersiniae became evident by
perimental infection of mice; in contrast to wild-type mice, IL-10-/-
ce were highly resistant against Yersinia infection, as shown by lower
cterial load in spleen and liver, absent abscess formation in these
gans, and survival.

/3,AB/38 (Item 2 from file: 155)
ALOG(R)File 155:MEDLINE(R)
format only 2003 The Dialog Corp. All rts. reserv.

506986 21391858 PMID: 11500471
%PcrV% immunization enhances survival of burned %Pseudomonas%
eruginosa-infected mice.
Holder I A; Neely A N; Frank D W
Department of Microbiology, Shriners Hospital for Children, Cincinnati,
o 45229, USA. iaholder@juno.com
Infection and immunity (United States) Sep 2001, 69 (9) p5908-10,
SN 0019-9567 Journal Code: 0246127
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
urned %Pseudomonas% aeruginosa-infected mice immunized against %PcrV%, a
e III virulence system translocating %protein%, showed significantly
anced survival compared to controls. Survival was non-O serotype
cific and correlated with a reduced systemic microbial load. Infection
h a high-level toxin A-producing strain required supplemental antitoxin
atment to enhance survival.

3,AB/39 (Item 3 from file: 155)
LOG(R)File 155:MEDLINE(R)
format only 2003 The Dialog Corp. All rts. reserv.

46146 21105993 PMID: 11169103
crV is a channel size-determining component of the Yop effector
nslocon of Yersinia.
olmstrom A; Olsson J; Cherepanov P; Maier E; Nordfelth R; Pettersson J;
z R; Wolf-Watz H; Forsberg A
epartment of Microbiology, FOA NBC-Defence, S-901 82 Umea, Sweden.
olecular microbiology (England) Feb 2001, 39 (3) p620-32, ISSN
0-382X Journal Code: 8712028